Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
11/2009 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions November recently filed with US Patent Office 11/09

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
11/26/2009 > 153 patent applications in 109 patent subcategories. recently filed with US Patent Office

20090291878 - Modulators of protein phosphatase 2a holoenyme: Atomic coordinates for human serine/threonine protein phosphotase 2A (PP2A) holoenzyme, as well as methods for using these atomic coordinates to prepare inhibitors of PP2A and inhibitors prepared using such methods are provided herein. A biochemical analysis of the interactions of PP2A holoenzyme is also provided. Compositions including mimetics and small... Agent: Pepper Hamilton LLP

20090291877 - Treatments using citrulline: The invention provides a method and formulation for the treatment or maintenance of conditions that would be benefited from increasing or maintaining Arginine levels in the blood, and having improved taste characteristics over current Arginine supplementations. Further, this maintenance of Arginine levels in the blood will be beneficial in acute... Agent: Nestle Healthcare Nutrition

20090291881 - Coatings for drug delivery devices: A polymer coating for medical devices based on a polyolefin derivative. A variety of polymers are described to make coatings for medical devices, particularly, for drug delivery stents. The polymers include homo-, co-, and terpolymers having at least one olefin-derived unit and at least one unit derived from vinyl alcohol,... Agent: Squire, Sanders & Dempsey LLP

20090291880 - Methods comprising desmopressin: The present disclosure is directed to gender, age, and dose effects of desmopressin on reducing nocturnal voids, increasing an initial period of undisturbed sleep, and/or reducing nocturnal urine volume.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090291879 - Modulation of cartilage homeostasis by active domains of cell binding extracelular matrix molecules: A linear or cyclic peptide and the use of said peptide in medicine and especially in the manufacture of a medicament for the treatment and/or prophylaxis of a disease associated with inflammatory mediated cartilage destruction. The minimal core sequence of the linear or cyclic peptide is WLEAK (SEQ ID No.... Agent: Lynn E Barber

20090291882 - Coatings for drug delivery devices: A polymer coating for medical devices based on a polyolefin derivative. A variety of polymers are described to make coatings for medical devices, particularly, for drug delivery stents. The polymers include homo-, co-, and terpolymers having at least one olefin-derived unit and at least one unit derived from vinyl alcohol,... Agent: Squire, Sanders & Dempsey LLP

20090291883 - Combination of an immunosuppressive agent and nonsteroidal anti -inflammatory drugs to treat disease: The present invention provides methods and compositions for the treatment and prevention of neoplasia by administering an effective amount of a NSAID in combination with an effective amount of an immunosuppressant agent. In particular, the present invention provides methods and compositions for the treatment and prevention of neoplasia by administering... Agent: Ronald I. Eisenstein

20090291893 - Compositions for the prevention and treatment of neuroinjury and methods of use thereof: A method for preventing or ameliorating secondary neuronal injury and inflammation following traumatic brain injury (TBI) is disclosed. The method comprises the step of administering into a subject in need of such treatment an effective amount of a pharmaceutical composition containing a neuregulin (NRG), a variant of NRG, or an... Agent: Morris Manning Martin LLP

20090291885 - Conjugated toxin peptide therapeutic agents: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells... Agent: Amgen Inc.

20090291889 - Diagnostic assay and method of treatment for miscarriage risk or premature birth involving macrophage inhibitory cytokine-1 (mic-1): Methods for diagnosing risk of miscarriage and/or premature birth, foetal abnormalities, cancer (e.g. prostate cancer) and inflammatory disease (e.g. rheumatoid arthritis) are disclosed which involve determining abnormal levels of macrophage inhibitory cytokine-1 (MIC-1) in a body sample or, otherwise, determining the presence of a MIC-1 variant protein. Also disclosed are... Agent: Nixon & Vanderhye, PC

20090291890 - Factor vii polypeptides that are modified and uses thereof: Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.... Agent: K&l Gates LLP

20090291896 - Genes encoding novel proteins with pesticidal activity against coleopterans: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding δ-endotoxins having pesticidal activity against pests of the order Coleoptera. The invention further provides mutagenized nucleic acids that have been modified to encode endotoxins having improved pesticidal activity and/or altered pest specificity. Particular... Agent: Alston & Bird LLP Pioneer Hi-bred International, Inc.

20090291895 - Methods and compositions for the treatment of inflammatory diseases: Compositions and methods for treating inflammatory disorders are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20090291894 - Methods for treating progressive cognitive disorders related to neurofibrillary tangles: The described invention provides methods for treating or preventing progression of a progressive cognitive disease, disorder or condition, and methods for improving resilience of cognitive function in a subject in need thereof.... Agent: Greenberg Traurig, LLP

20090291897 - Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist: This invention relates to methods for treating unwanted body weight loss (such as cachexia), eating disorders (such as anorexia nervosa), or opioid-induced emesis by peripheral administration of a trkB agonist. The invention also relates to compositions and kits comprising a trkB agonist.... Agent: Pfizer Inc

20090291888 - Modulators of tnf receptor associated factor (traf), their preparation and use: A DNA sequence encoding a protein capable of binding to a tumor necrosis factor receptor-associated factor (TRAF) molecule, TRAF-binding proteins, their isoforms, analogs, fragments and derivatives encoded by the DNA sequence, their methods for the production of the DNA sequences and proteins, and the uses for the DNA sequence and... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090291884 - Proteins for use in diagnosing and treating infection and disease: The present invention describes a composition comprised on cystatin A and at least one histone used in diagnostic tools and for the treatment of diseases associated with reduced T helper cell counts such as HIV-1 infection, AIDS, ARC, multiple sclerosis, chronic fatigue syndrome, heumatoid arthritis, Alzheimer's disease, dermatitis, type 1... Agent: Berliner & Associates

20090291887 - Proteins of the sdf-1-family for the manufacturing of a medicament: Use of a protein of the SDF-1-family for the manufacturing of a medicament for the improvement of the plasticity and/or regeneration of axons upon their lesion.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090291892 - Slpa as a tool for recombinant protein and enzyme technology: Disclosed are a recombinant DNA molecule encoding a fusion protein comprising a SlpA chaperone and a target polypeptide wherein human FK506 binding proteins (FKBPs) are excluded as target polypeptides, a corresponding expression vector encoding said fusion protein as well as host cells transformed with said expression vector. Also disclosed are... Agent: Roche Diagnostics Operations Inc.

20090291886 - Transmucosal delivery of peptides and proteins: Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090291891 - Vegf variant that lacks vegfr-1 binding activity and its use in promotion of re-endothelization and prevention of in-stent restenosis: A VEGF145 polypeptide devoid of a VEGFR-1 binding activity and methods of making and using same in preventing and/or treating restenosis are provided.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090291898 - Novel anti-microbial peptidomimetic compounds and methods to calculate anti-microbial activity: This invention encompasses synthetic antimicrobial peptide analogs having certain un-natural amino acids, including the un-natural amino acids hydrophobic tetrahydroisoquinolinecarboxylic acid (Tic) and octahydroindolecarboxylic acid (Oic), incorporated into the polypeptide backbone. These antimicrobial peptides (AMPs) are useful to treat infection in humans and other mammals of such bacteria as Gram positive... Agent: U.s. Army Medical Research And Material Command Attn: Mcmr-za-j ( Ms. Elizabeth Arwine)

20090291899 - Selective modulation of receptor signalling: The present invention relates to a method of selectively modulating a signalling pathway of interest controlled by a cell receptor involved in signalling through multiple signalling pathways The method includes exposing the receptor to an agent that modulates signalling by the receptor through the signalling pathway of interest and does... Agent: Heslin Rothenberg Farley & Mesiti PC

20090291900 - Methods for treatment of headaches by administration of oxytocin: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.... Agent: Morrison & Foerster LLP

20090291901 - Control of radiation injury: The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides... Agent: Traskbritt, P.C.

20090291902 - Inhibitors of serine proteases, particularly hcv ns3-ns4a protease: or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising... Agent: Vertex Pharmaceuticals Inc.

20090291903 - Substituted pyrrolidine amides as modulators of the histamine h3 receptor: Certain substituted pyrrolidine amide compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20090291904 - Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof: The present invention relates to novel jasmonate derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers.... Agent: Fennemore Craig

20090291905 - Fungal phytotoxin fusicoccin for the treatment and diagnosis of coagulation-correlated pathologies: The present invention concerns the use of tricyclic terpenes chosen from the group consisting of fusicoccin, ophyobolins or cotylenins for the therapy and diagnosis of coagulation-correlated pathologies such as Bernard-Soulier syndrome (BSS), von Willebrand disease (vWD), Glanzmann's thrombasthenia or thrombocytopenia.... Agent: Arent Fox LLP

20090291906 - Oligomeric compounds and compositions for use in modulation of small non-coding rnas: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment... Agent: Pepper Hamilton LLP

20090291907 - Oligomeric compounds and compositions for use in modulation of small non-coding rnas: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment... Agent: Pepper Hamilton LLP

20090292003 - Cell penetrating peptides for intracellular delivery of molecules: The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9RALX9RX1LX2RSLX9X3X4X5X6X7X8 (SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090292008 - Compositions and methods for treatment of prostate and other cancers: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for... Agent: Larson & Anderson, LLC

20090292006 - Compounds and methods for modulating expression of dgat2: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are... Agent: Mcdermott Will & Emery

20090292005 - Galactose derivative, drug carrier and medicinal composition: e

20090292007 - Inhibition of tace or amphiregulin for the modulation of egf receptor signal transactivation: The present invention relates to the modulation of transactivation of receptor tyrosine kinases by G protein or G protein-coupled receptor (GPCR) mediated signal transduction in a cell or an organism comprising inhibiting the activity of the metalloprotease TACE/ADAM17 and/or the activity of the receptor tyrosine kinase ligand amphiregulin.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090292004 - Methods to identify compounds useful for the treatment of proliferative and differentiative disorders: The present invention relates to the discovery and characterization of activity of Fbp1, a substrate-targeting ubiquitin ligase subunit. The invention encompasses interactions between Fbp1 and its substrates, including Fbp5, β-Catenin, and IκBα. The invention also encompasses interactions between the Fbp1 isoform β-Trcp2 and its substrates, including Fbp5, b-Catenin, and IκBα.... Agent: Jones Day

20090292009 - Modulation of stat 6 expression: Compounds, compositions and methods are provided for modulating the expression of STAT 6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT 6. Methods of using these compounds for modulation of STAT 6 expression and for diagnosis and treatment of disease associated with expression of STAT 6 are provided.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090292002 - Nucleotide and amino acid sequences relating to respiratory diseases and obesity: This invention relates to genes identified from human chromosome 12q23-qter, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and isolated polypeptides or peptides encoded thereby. The invention further relates to vectors and... Agent: Morgan & Finnegan, L.L.P.

20090291908 - Use of thiophoshonoformic acid and nrtis to treat viral infections: This invention provides for a method of synergistically reducing viral load in a patient infected with a virus. The method comprises the oral co-administering an amount of thiophosphonoformic acid and an amount of a nucleoside or nucleotide reverse transcriptase inhibitor in a synergistic combination.... Agent: Townsend And Townsend And Crew, LLP

20090291909 - Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue: A composition for the protection, treatment and repair and for reducing the inflammation of connective tissue in mammals and a method for the treatment of connective tissue in mammals by the administration of the composition. The composition includes S-Adenosylmethionine (SAM), and a component selected from an aminosugar or salts thereof... Agent: Arent Fox LLP

20090291910 - Agent and food for preventing/improving functional digestive disorder: The present invention provides an agent and a food for the prophylaxis or improvement of a functional gastrointestinal disorder, which contains, as an active ingredient, at least one kind selected from glutamic acid, 5′-nucleotide and a salt thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090291912 - Chitosan-containing protective composition: Body tissue and structures may be protected using a fluid containing a mixture of partially crosslinked polysaccharide and a further crosslinker. The mixture desirably is sprayable, forms a fluid protective layer via in situ crosslinking, desirably does not drip or run from a treatment site, and may avoid the use... Agent: Iplm Group, P.A.

20090291911 - Rehydratable polysaccharide particles and sponge: Tissue and other body structures may be protected using a hydrated composition made from free-flowing substantially collagen-free rehydratable polysaccharide particles and rehydratable polysaccharide sponges. Rehydration of the particles without clumping may be carried out be dispersing the particles in a biocompatible water-miscible polar dispersant such as ethanol and combining the... Agent: Medtronic, Inc.

20090291913 - Factor xa inhibitor formulation and method: An injectable Factor Xa inhibitor formulation is provided which includes the Factor Xa inhibitor razaxaban or apixaban, a solubilizing agent which is a substituted β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBE-CD) or hydroxypropyl-β-cyclodextrin (HPB-CD), and water. A method for preventing or treating venous thrombosis, deep venous thrombosis and acute coronary syndrome... Agent: Fitzpatrick Cella (bms)

20090291914 - Hyaluronic acid oligosaccharide fractions and drugs containing the same: A method for promoting expression of a heat shock protein, or for inhibiting cell injury or cell death, or for treating a disease for which cell or tissue protection is desired, or for promoting production of IL-10, or for inhibiting production of IL-8, by administering an effective amount of a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090291915 - Silicon compounds and their use: A compound of any of formulae (I) to (III) wherein at least one of Y and Z includes a Si atom, is of utility in therapy.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090291916 - Trihydroxy polyunsaturated eicosanoid: The invention features methods for the preparation of naturally occurring trihydroxy polyunsaturated eicosanoids and their structural analogs. The invention further provides new derivatives and analogs of trihydroxy polyunsaturated eicosanoids that can be prepared according to these methods. The invention also provides compositions and methods using trihydroxy polyunsaturated eicosanoid derivatives for... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20090291917 - Boron-containing small molecules as anti-inflammatory agents: Compounds and methods of treating anti-inflammatory conditions are disclosed.... Agent: Morgan, Lewis & Bockius LLP (sf)

20090291918 - Proteasome inhibitors and methods of using the same: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome... Agent: Ross J. Oehler Cephalon, Inc.

20090291919 - Compositions and methods for treating or preventing ophthalmic light toxicity: Methods are disclosed for treating ophthalmic conditions related to the production of toxic visual cycle products that accumulate in the eye, and are associated with reactions of the visual cycle during medical procedures that expose the eye to light, most commonly the various forms of ophthalmic surgery. Compounds and compositions... Agent: Jeffrey D. Hsi Edwards Angell Palmer & Dodge LLP

20090291920 - Detection of steroid receptors on circulating carcinoma cells and treatment: The expression of a steroid receptor from circulating carcinoma cells in a blood sample is detected by isolating the carcinoma cells from the blood sample, making an extract from the isolated carcinoma cells and then performing on the extract a sensitive immunoassay capable of detecting the carcinoma cell-associated steroid receptor.... Agent: Wellstat Management Company. LLC

20090291922 - Anti-proliferative compounds, compositions, and methods of use thereof: e

20090291921 - Integrase inhibitors: Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.... Agent: Gilead Sciences Inc

20090291923 - Trioxane dimers having high anticancer and long-lasting antimalarial activities: The invention provides novel trioxane dimers having formulae III, IV or V: methods for their preparation, pharmaceutical compositions containing these compounds, and methods for treating cancer and/or malaria using these compounds and compositions.... Agent: Townsend And Townsend And Crew, LLP

20090291924 - Drug design for tubulin inhibitors, compositions, and methods of treatment thereof: The present invention relates to a computer-assisted method of a designing of a tubulin inhibitor comprising: a) determining an interaction between a tubulin protein and a chemical known to bind the tubulin protein by evaluating a binding of the tubulin protein to the chemical known to bind the tubulin protein;... Agent: Bipar Sciences Inc. C/o Mofo

20090291925 - Bioactive polymeric liquid formulations of absorbable, segmented aliphatic polyurethane compositions: Bioactive liquid formulations are formed of combinations of absorbable, segmented aliphatic polyurethane compositions and liquid polyether for use as vehicles for the controlled release of at least one active agent for the conventional and unconventional treatment of different forms of cancer and the management of at least one type of... Agent: Leigh P. Gregory

20090291926 - High yield and rapid synthesis methods for producing metallo-organic salts: A new method for preparing salts of metal cations and organic acids, especially divalent salts of alkaline earth metal ions from group II of the periodic system and carboxylic acids. The method comprising the use of a high temperature (about 90° or more) and, optionally. high pressure, in order to... Agent: Jones Day

20090291927 - Extended cycle multiphasic oral contraceptive kit: A multiphasic contraceptive kit is disclosed that may be used to practice a multiphasic method of contraception that provides for sequentially administering to a female of child bearing age: (a) a Phase I composition containing a progestogen in an amount equivalent to about 0.5 to about 1.5 mg norethindrone acetate... Agent: Fitzpatrick Cella Harper & Scinto

20090291928 - Composition for amelioration/prevention of adverse side effect in steroid therapy: Provided is a composition containing isoleucine, leucine and valine as active ingredients for improving or suppressing side effects associated with a steroid treatment and a composition for suppressing muscular atrophy-related gene. The composition improves or suppresses side effects in a steroid treatment such as muscular atrophy, muscular pain, arthritic pain,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090291929 - Steroids having a mixed androgenic and progestagenic profile: The invention provides for compounds having formula (1) wherein; R1 is O, (H,H), (H,OH), or NOR, with R being hydrogen, (C1-6) alkyl or (C1-6) acyl; R2 is hydrogen, methyl, ethyl, or ethenyl; R3 is hydrogen, methyl, ethyl, ethenyl, fluoro, or chloro; R4 is methyl, or ethyl; R5 is hydrogen, methyl,... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090291930 - Fibrous calcium pyrophosphate particles and methods of making and using same: Fibrous calcium pyrophosphate particles with a unique fibrous nanostructure are disclosed. The invention includes a composition, comprising fibrous particles, wherein the fibrous particles include fibers and the fibers include calcium and pyrophosphate. Also included are methods for making calcium pyrophosphate particles wherein solutions of calcium salt and pyrophosphate salt are... Agent: Pauley Petersen & Erickson

20090291931 - Compositions with enhanced elasticizing activity: Compositions for improving the elasticity of the vagina and of the perineum during the last trimester of pregnancy, include combining a thiolated compound or mixture thereof with an ester of organic acid or mixture thereof. The compositions according to the present invention improve the elastic properties of the vaginal and/or... Agent: The Firm Of Hueschen And Sage

20090291932 - Pharmaceutical solid state forms: The invention provides and describes solid state 17α-ethynyl-5α-androstane-3α,17β-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-5α-androstane-3α,17β-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17α-ethynyl-5α-androstane-3α,17β-diol in a described solid state form and use... Agent: Hollis-eden Pharmaceuticals, Inc.

20090291933 - Solid state forms of a pharmaceutical: The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state... Agent: Hollis-eden Pharmaceuticals, Inc.

20090291934 - Method for decomposing an allergen: e

20090291935 - X-nitro compounds, pharmaceutical compositions thereof and uses thereof: The present invention provides X-nitro compound, pharmaceutical compositions of X-nitro compounds and methods of using X-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.... Agent: Morgan, Lewis & Bockius, LLP

20090291936 - Oxime derivative and preparations thereof: e

20090291937 - Kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20090291938 - Polo-like kinase inhibitors: e

20090291939 - Treating alcohol and or substance abuse by antagonizing alpha 2 adrenergic receptors with weak dopamine blocking: Certain atypical antipsychotic medications (particularly clozapine) or combinations of medications are useful to treat alcohol or other substance abuse, particularly in the general (non-schizophrenic) population. Generally stated, one aspect of the invention features a method of treating a patient suffering from alcohol or other substance abuse by administering to the... Agent: Fish & Richardson PC

20090291940 - Aminopyrrolidine compound: Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MC4 receptor antagonistic effect.... Agent: Sughrue Mion, PLLC

20090291941 - Tyrosine kinase inhibitors: The present invention relates to pyrido[3,2-c]benzazocinone derivatives and related compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat... Agent: Merck And Co., Inc

20090291942 - Imidazo pyridine derivatives: The invention relates to novel imidazopyridine derivatives and to their use in the treatment of diseases and disorders which may e.g. involve angiogenesis and/or pain, including autoimmune and inflammatory diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090291943 - Process for preparing diaminophenothiazinium compounds: Process for preparing compounds of the diaminophenothiazinium type comprising a step for purification of derivatives (II). The products resulting from this process have a high degree of purity. Use of these compounds for the preparation of medicaments.... Agent: Alston & Bird LLP

20090291944 - Antimicrobial compositions and methods of use: In one aspect, compositions provide antimicrobial therapy as topical disinfectants. Particularly, one aspect relates to an alcohol containing antimicrobial composition that includes at least one paraben, a redox compound and an organic acid at a concentration of from about 1.5 percent to about 10 percent by weight, based on the... Agent: Krieg Devault LLP

20090291945 - Cysteine protease inhibitors: To provide a compound having an excellent cysteine protease inhibitory effect, and to provide a drug for treatment or prevention of the disease selected from the group consisting of osteoporosis, osteoarthritis, chronic rheumatoid arthritis, Paget's disease of bone, hypercalcemia, bone metastasis of cancer, and ostealgia. A compound represented by formula... Agent: Sughrue Mion, PLLC

20090291946 - Lactam compounds and their use as pharmaceuticals: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or... Agent: Fish & Richardson PC

20090291947 - Proline analogs as ligands for cannabinoid receptors: The present invention relates to Proline Analog Compounds that are ligands for cannabinoid receptors, compositions comprising a Proline Analog Compound and a pharmaceutically-acceptable carrier, methods of making such Proline Analog Compounds, and methods for treating or preventing a Condition comprising administering an effective amount of a Proline Analog Compound to... Agent: Dechert LLP

20090291948 - Sulfonamide peri-substituted bicyclics for occlusive artery disease: e

20090291950 - Bicyclic heteroaryl inhibitors of pde4: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PD E4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.... Agent: Global Patent Group - Kal

20090291949 - Substitute isoquinolines useful in the treatment of diseases such as cancer and atherosclerosis: e

20090291951 - Novel cyclic compound having pyrimidinylalkylthio group: R1 and R2 independently represent a hydrogen atom, an alkyl group, an aryl group, an aromatic heterocyclic group or the like; R3 represents a hydrogen atom, a halogen atom, a hydroxy group, an alkoxy group, an aryloxy group, an alkyl group, an aryl group, an amino group, an alkylamino group... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090291952 - Modulators of pharmacokinetic properties of therapeutics: The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.... Agent: Gilead Sciences Inc

20090291953 - Pharmaceutical salts of reboxetine: The present invention relates to novel crystalline, water-soluable salts of the 2S,3S enantiomer of reboxetine, which are the fumarate and succinate salts thereof, to a process for their preparation, to their utility in therapy and to pharmaceutical compositions containing them.... Agent: Pfizer Inc. Patent Department

20090291954 - Medical use of triazine derivatives: Compounds of formula (I) especially where R1 is an optionally substituted alkyl, aralkyl or heterocyclyl-alkyl group, are shown to have activity as sodium channel blockers or as antifolates. Some novel compounds where R1 is an aralkyl or hetero-cyclyl-alkyl are disclosed.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090291955 - Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Azacyclohexane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis;... Agent: Merck And Co., Inc

20090291956 - Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same: The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide,... Agent: Fish & Richardson PC

20090291957 - Heterocyclic derivatives and their use as therapeutic agents: e

20090291958 - Substituted pde5 inhibitors: Provided herein are substituted PDE5 inhibitors of Formula 1, and processes of preparation and pharmaceutical compositions thereof. Also provided are methods of their use for the treatment and/or management of hypertension, erectile dysfunction, and/or the inability to maintain improved erectile function.... Agent: Global Patent Group - Apx

20090291959 - Caspase inhibitors based of pyridazinone scaffold: The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same.... Agent: Birch Stewart Kolasch & Birch

20090291960 - Pyrrolinidium derivatives as m3 muscarinic receptors: Compounds of formula (I) in salt or zwitterionic form, wherein R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds... Agent: Novartis Corporate Intellectual Property

20090291961 - Combination of an mek inhibitor and the src kinase inhibitor azd0530 for use in the treatment of cancer: The invention relates to a combination for use in the treatment of cancer comprising a MEK inhibitor and the Src kinase inhibitor AZD0530.... Agent: Astrazeneca R&d Boston

20090291962 - 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as p2y12 receptor: The invention relates to 2-phenyl-6-aminbcarbonyl-pyrimidinc derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. Formula (1).... Agent: Hoxie & Associates LLC

20090291963 - Substituted indoles: Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R1, D, E, R12, p, X1, E, G, X2 and Z are as defined in claim 1, exhibit particular actions on the central nervous system, especially 5HT reuptake-inhibiting and 5 HTx-agonistic and/or -antagonistic actions and... Agent: Millen, White, Zelano & Branigan, P.C.

20090291964 - Potentiators of antibacterial activity: The present invention relates to compounds that potentiate the activity of antibacterials. The present invention also relates to compositions useful in treating bacterial infection in mammals, and methods therewith. The present invention also relates to a method of inhibiting bacterial efflux of an antibiotic, thereby increasing the efficacy of the... Agent: Vertex Pharmaceuticals Inc.

20090291965 - Histone deacetylase inhibitors with aryl-pyrazolyl-motifs: The present invention relates to a novel class of histone deacetylase inhibitors with aryl-pyrazolyl motifs. The compounds of this invention can be used to treat cancer. The compounds of this invention are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby... Agent: Merck And Co., Inc

20090291966 - Method of treating anxious major depressive disorder: The invention is directed to using 4-{(3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-yl]methyl}-N,N-diethylbenzamide, or enantiomer thereof, or pharmaceutically acceptable salt thereof, and/or mixture thereof to treat anxious major depressive disorder (AMDD).... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090291967 - Small molecule modulators of cell adhesion: e

20090291969 - Fungicide hydroximoyl-tetrazole derivatives: The present invention relates to hydroximoyl-tetrazole derivatives of formula (I) wherein T represent a tetrazolyl substituent, A represents a carbo- or heterocycle, L1 and L2 represent various linking groups and Q represents a 5-membered heterocycle, their process of preparation, their use as fungicide active agents, particularly in the form of... Agent: Ostrolenk Faber Gerb & Soffen

20090291970 - Substituted aminoethers for the treatment of alzheimer's disease: The invention provides compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090291968 - Substituted indazole derivatives, their manufacture and use as pharmaceutical agents: e

20090291971 - Heteroaryl ethers and processes for their preparation: The present invention relates to processes for the preparation of heteroaryl ethers. In some embodiments, the processes relate to cross coupling reactions between triazol-1-yloxy and triazol-1-yl heterocycles with aryl boronic acids. In a further aspect, this invention also relates to compounds that are useful for the treatment of oncological diseases... Agent: Wyeth Patent Law Group

20090291972 - Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer: The disclosure herein relates to nuclear hormone receptors including steroid hormone receptors, for example in connection with estrogen, progesterone, and androgen. Embodiments of compositions and methods are disclosed including such relating to compounds, including substituted theophyllines, capable of functioning as inhibitors of estrogen receptor alpha-mediated gene expression and having the... Agent: Greenlee Winner And Sullivan P C

20090291973 - Novel quinazoline derivatives and their medical use: This invention relates to novel quinazoline derivatives having medical utility, to use of the quinazoline derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the quinazoline derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which... Agent: Birch Stewart Kolasch & Birch

20090291974 - Bosentan salts: Stable acid addition salts of bosentan useful for the purification of bosentan base; the salts are in solid state and the starting acid has a pKa lower than 3.... Agent: SynthonIPInc

20090291975 - Dual opioid pain therapy: Provided are pharmaceutical compositions and methods for the alleviation of pain in a patient with optimal ratios of morphine and oxycodone that provide superior analgesic efficacy and lower incidence of adverse side effects compared to morphine and oxycodone alone. The pharmaceutical compositions comprise morphine and oxycodone, or pharmaceutically acceptable salts... Agent: King & Spalding

20090291976 - Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors: A method of inhibiting excitotoxicity by indirectly activating α4β2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of α7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate α4β2 nAChRs and can be used to treat neurodegenerative diseases, including,... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090291977 - Chromane derivatives useful as acid pump antagonists: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: R′, R2, R3, R4, R5, R6, R7, R8 A and B are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the method of treatment and the use,... Agent: Pfizer Inc. Patent Department

20090291978 - Enzyme inhibitors: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the... Agent: Banner & Witcoff, Ltd.

20090291979 - Tricyclic-bridged piperidinylidene derivatives as delta opioid modulators: m

20090291980 - Triglyceride-lowering agent and hyperinsulinism-ameliorating agent:

20090291981 - 5-lipoxygenase-activating protein inhibitor: Described herein is the FLAP inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, including solvates, and polymorphs thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the FLAP... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090291983 - 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents: s

20090291982 - New substituted oxindole derivative 352: 6-(5-cyano-2-hydroxy-1H-indol-3-yl)pyridine-3-carboxylic acid or a pharmaceutically acceptable salt thereof, in an essentially pure and isolated form, pharmaceutical formulations containing said compounds, to the use of said active compounds in therapy, and methods of prevention and/or treatment of conditions associated with glycogen synthase kinase-3 related disorders, comprising administering to a mammal, including... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090291984 - Substituted pyrazoles, compositions containing these, method of production and use: (

20090291986 - Composition and method of treating facial skin defect: This invention relates to a subcutaneous deliverable composition containing an agonist of the peroxisome proliferator-activated receptor-gamma, and a method for treating facial skin defects in a mammalian subject using the subcutaneous deliverable composition.... Agent: Philip S. Johnson Johnson & Johnson

20090291985 - Methods and kit for early detection of acute coronary syndrome and prediction of adverse cardiac events: The invention provides methods for early diagnosis or detection of acute coronary syndrome and prediction of adverse cardiac events on the basis of elevations of catalytic iron in biological fluid of a human subject. An embodiment of the invention provides a method for early detection of acute coronary syndrome (ACS)... Agent: GlobalIPServices PLLC

20090291987 - Novel polymorph of (5-amino-6-methoxy-3-pyridincarbonyl) carbamic acid 2-(s)-hydroxymutilin 14-ester: The present invention relates to a novel polymorph, to processes for the preparation of the polymorph and to the use of the polymorph in medicine, particularly antibacterial therapy.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090291989 - Isothiocyanate compounds, pharmaceutical compositions, and uses thereof: Provided herein are compositions of matter and pharmaceutical compositions thereof, for use in inhibiting the growth of various microbial pathogens, including bacteria, fungi, protozoa, and viral pathogens. Also provided herein are methods of treating microbial diseases/infections and cancer with the compositions. The compositions are additionally useful in wood preservation and... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090291988 - Reversible inhibitors of monoamine oxidase a and b: The instant invention relates to compounds of formula I, diagrammed below, wherein R3, E, D and Y are defined in the application, which are useful as reversible inhibitors of monoamine oxidase-B and/or monoamine oxidase-A, and therefore useful to treat or prevent neurological diseases or conditions in mammals, preferably humans.... Agent: Merck And Co., Inc

20090291991 - Isoindoline compounds and methods of their use: Novel isoindoline compounds are disclosed. Methods of treating, preventing and/or managing cancer, diseases and disorders associated with, or characterized by, undesired angiogenesis, and diseases and disorders mediated by PDE 4, using the compounds are also disclosed.... Agent: Jones Day

20090291990 - Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents: Oxadiazolyl-phenoxyalkylisoxazoles and pharmaceutically acceptable salts thereof, compositions comprising oxadiazolyl-phenoxyalkylisoxazole compounds or pharmaceutically acceptable salts thereof and methods for using oxadiazolyl-phenoxyalkylisoxzazole compounds or pharmaceutically acceptable salts thereof as anti-picornaviral agents are described herein. The methods include using pleconaril as a prodrug for conversion to anti-picornaviral compounds in vivo.... Agent: Dann, Dorfman, Herrell & Skillman

20090291992 - Androgen receptor-ablative agents: Compounds of the thiazolidinedione family are provided and shown to be effective androgen receptor ablative agents that can be used in methods of treating or preventing cancer or precancer, including prostate cancer. Also provided are methods of treating or preventing cancer by administering a therapeutically effective amount of one of... Agent: Calfee Halter & Griswold, LLP

20090291993 - Difluorophenol derivatives and their use: The present application relates to novel difluorophenol derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090291994 - Use of pyraclostrobin as safener for triticonazole for controlling harmful fungi: The use of the compounds I and II in a process for controlling harmful fungi using mixtures of the compounds I and II und the use of the compounds I and II for preparing such mixtures, and also compositions comprising such mixtures.... Agent: Birch Stewart Kolasch & Birch

20090291995 - 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine): An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090291996 - Caspofungin free of caspofungin co: The present invention provides Caspofungin and salts thereof substantially free of Caspofungin C0 and salts thereof. The present invention also provides processes for the preparation of said Caspofungin and salts thereof and processes for the determination of the amount of Caspofungin C0 and salts thereof present in Caspofungin and salts... Agent: Kenyon & Kenyon LLP

20090291997 - Carvedilol dihydrogen phosphate monohydrate: Disclosed herein is crystalline carvedilol dihydrogen phosphate monohydrate having high aqueous solubility and the process for preparation thereof. The invention further discloses methods for treating hypertension, congestive heart failure and angina in a mammal, using pharmaceutical compositions comprising the compound of invention.... Agent: Proteus Patent Practice LLC

20090291998 - Eponemycin and epoxomicin analogs and uses thereof: The present invention provides compounds having formula (1): wherein R1-R6, A, J, D, A, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory... Agent: Myers Bigel Sibley & Sajovec

20090291999 - Agent exhibiting a neurotropic, neuromodulator, cerebrovascular and anti-stroke activity: The invention relates to medicine, in particular to pharmacology and to medicinal agents exhibiting a neurotropic and cerebrovascular activity. The novelty of the invention consists in that an N-carbomoyl-methyl-4-phenyl-2-pyrrolidon agent injected into an organism displays an universal pronounced effect in the form of the one hundred percent survival of animals,... Agent: The Nath Law Group

20090292000 - Pyrrolidine derivatives as prostaglandin modulators: Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090292001 - Tricyclic derivatives as potent and selective histone deacetylase inhibitors: The present invention relates to certain tricyclic derivatives which are capable of inhibiting histone deacetylases. The compounds of this invention are therefore useful in treating diseases associated with abnormal histone deacetylase activities. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds, and methods of... Agent: Eckert Seamans Cherin & Mellott

20090292010 - Sweetener compositions and methods of making them: The present invention provides compositions comprising sucralose and 4-amino-5,6-dimethylthieno[2,3-d]pyrimidine-2(1H)-one or salts, solvates, and/or esters thereof and methods of making the compositions by spray drying. The present invention also provides ingestible compositions comprising compositions of the present invention and methods of making such foods. The present invention also includes a process... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090292011 - Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases: Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a... Agent: Cantor Colburn, LLP

20090292012 - Therapeutic agent: A therapeutic agent or prophylactic agent for a disease requiring an anti-foaming action for a cell and/or an inhibitory action for acyl-CoA cholesterol acyltransferase in treatment or prevention, characterized in that the therapeutic agent or prophylactic agent comprises as an effective ingredient a processed product derived from Peucedanum japonicum.... Agent: Birch Stewart Kolasch & Birch

20090292013 - In-situ forming implant for animals: The invention relates to a composition, comprising a thermoplastic polymer, a rate modifying agent and a biologically active agent, useful as a slow-release drug-delivery implant in the body of a human or animal that can be administered in liquid form into the body.... Agent: Novartis Corporate Intellectual Property

20090292014 - Benzofuran derivatives useful for treating hyper-proliferative disorders: The invention relates to novel benzofuran derivatives, processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090292015 - Stable high vitamin c content polyol-in-oil emulsified system and its preparation: The present invention is directed to a polyol-in-oil composition used to transport and stabilize Vitamin C. The composition includes 0.5 wt % to 5 wt % of at least one emulsifier, 0.1 wt % to 5 wt % of at least one stabilizer, 0.01 wt % to 20 wt %... Agent: Scully Scott Murphy & Presser, PC

20090292016 - Stable pharmaceutical compositions containing pravastatin: Stabilized pharmaceutical preparations containing a drug which is sensitive to a low pH environment, such as pravastatin are disclosed in which pravastatin degradations is prevented with a buffering agent. The basic excipient enhances storage stability.... Agent: Hedman & Costigan P.C.

20090292017 - Therapeutic compositions: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.... Agent: Foley & Lardner LLP

20090292018 - Dicarbonic acid derivatives, metastasis inhibitors and agents increasing chemotherapeutic activity of anti-tumor preparations, method for enhancing the cytostatic efficiency and metastasis process inhibiting method: The claimed compounds can be used in medical practice as low-toxic agents for enhancing anti-tumor and anti-metastasis effects of known cytostatics with a simultaneous 4-fold reduction of the therapeutic dose of cytostatics. The use of the proposed compounds in a combination with cisplatin at the minimum doses makes it possible... Agent: Fish & Richardson PC

20090292019 - Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof: There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer.... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20090292020 - Use of calcium salt of polyenoic acid in medical and cosmetic field: The present invention relates to a process for applying calcium polyenoic acid to medical cosmetology, wherein calcium polyenoic acid, calcium octadecadienic acid and calcium calendic acid are made into ointment or oil-type spraying agent for curing burn, scald, sun burn, bedsore, ulcer, cold injury, trauma. The calcium polyenoic acid and... Agent: David And Raymond Patent Firm

20090292021 - Anticonvulsive pharmaceutical compositions: Pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one substance having anti-ischemic effect, are disclosed.... Agent: Young & Thompson

20090292022 - Method of treating post-surgical acute pain: A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090292023 - Method of treating post-surgical acute pain: A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090292024 - Substituted propanamide derivative and pharmaceutical composition containing the same: [wherein, R1 represents a C6-C10 aryl group that may be substituted by a group selected from Substituent Group α, for example; R2 represents a C6-C10 aryl group that may be substituted by a group selected from Substituent Group α, for example; and X represents a hydroxyl group or a C1-C6... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090292025 - Novel crystalline forms of armodafinil and preparation thereof: The invention encompasses crystalline forms of armodafinil, processes for preparing the crystalline forms, and pharmaceutical formulation.... Agent: Kenyon & Kenyon LLP

20090292026 - Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.... Agent: Heslin Rothenberg Farley & Mesiti P.C.

20090292027 - Compositions for the treatment of signs of aging: e

20090292028 - Menthol-containing formulation: Thus, it is possible to obtain a formulation that remains stable over a long time, has a high light transmittance, and produces little foam when filled into a container and sprayed at a target area to inhibit contraction to facilitate observation of the area in endoscopic examination of the digestive... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090292029 - Bioabsorbable polymers from bioabsorbable polyisocyanates and uses thereof: Novel bioabsorbable and/or biocompatible polyurethanes, polyureas, polyamideurethanes and polyureaurethanes with tunable physical, mechanical properties and hydrolytic degradation profiles are provided for use in biomedical applications such as stents, stent coatings, scaffolds, foams, and films. The disclosed polymers may be derived from biocompatible and/or bioabsorbable polyisocyanates. The present invention also relates... Agent: Feldmangale, P.A.

  
11/19/2009 > 153 patent applications in 109 patent subcategories. recently filed with US Patent Office

20090286713 - Collagen receptor i-domain binding modulators: The present invention relates to a refined and detailed molecular model of the α2⊕1 integrin I-domain, especially the MIDAS and to the use of such a model for designing novel integrin modulators, especially α2β1 integrin modulators. The present invention further relates to novel α2β1 I-domain modulators, which are of therapeutic... Agent: Birch Stewart Kolasch & Birch

20090286714 - Novel molecules of the card-related protein family and uses thereof: Novel CARD-9, CARD-10, or CARD-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated CARD-9, CARD-10, or CARD-11 proteins, the invention further provides CARD-9, CARD-10, or CARD-11, fusion proteins, antigenic peptides and anti-CARD-9, CARD-10, or CARD-11 antibodies. The invention also provides CARD-9, CARD-10, or CARD-11 nucleic acid... Agent: Millennium Pharmaceuticals, Inc.

20090286715 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) a continuous liquid phase; (B) liquid droplets dispersed in said continuous phase; (C) a pharmaceutically-active compound; (D) an enhancer as described in U.S. Pat. No. 5,023,252; and (E) a hydrocolloid emulsifying agent; including, for example, a composition in which the liquid phase comprises an aqueous... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20090286716 - Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia: Pharmaceutical composition for parenteral administration comprising a meal related insulin peptide and an insulinotropic peptide.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090286717 - Glycopeptide antibiotic derivative: a

20090286719 - Modification of cupredoxin derived peptides and methods of use thereof: The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090286720 - Pharmaceutical composition for the diagnosis, prevention or treatment of a tumoral pathology comprising an agent modulating the polymerization state of actin: A pharmaceutical composition for the treatment, prevention or diagnosis of a tumoral pathology comprising an active agent which stabilizes an actin network of a cellular cytoskeleton.... Agent: Harness, Dickey & Pierce, P.L.C

20090286718 - Stable aqueous cyclosporin compositions: An aqueous ophthalmic composition is disclosed. The composition may comprise a cyclosporin in an amount from about 0.001 to about 1%, glycerin, and purified water, wherein the composition is substantially free of NaCl and sodium bisulfite or sodium metabisulfite. The composition is useful for the treatment of ocular conditions.... Agent: Brinks, Hofer, Gilson & Lione

20090286724 - Aggregable glp-1 analogue and sustained-release pharmaceutical composition: The present invention provides a GLP-1 analogue having a high association-aggregability or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition to be used for preventing or treating diabetes, hyperglycemia, a diabetic complication caused by diabetes or hyperglycemia, or obesity, using the same.... Agent: Darby & Darby P.C.

20090286722 - Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function: Peptide analogues and methods are provided for treating age-related symptoms of decreased pancreatic beta-cell function, including glucose intolerance, type 2 diabetes, beta-cell glucose insensitivity, insulin resistance and reduced insulin secretion.... Agent: K&l Gates LLP

20090286736 - Anti-inflammatory compounds and uses thereof: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell.... Agent: Mccarter & English, LLP Boston

20090286732 - Compounds for delivery of therapeutic and imaging moieties to nerve cells: where B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell; M is a moiety which performs a useful non-cytotoxic function when absorbed by a nerve cell, and can be a therapeutic moiety or an... Agent: Bozicevic, Field & Francis LLP

20090286727 - Dp-78-like nanobodies: The present invention relates to Nanobodies® that have a high degree of sequence homology with human variable domain sequences from the VH4 class and in particular with human DP-78 sequences, polypeptides containing such Nanobodies®, nucleic acids encoding such Nanobodies® and polypeptides, and uses thereof.... Agent: Wolf Greenfield & Sacks, P.C.

20090286729 - Epidermal growth factor receptor antagonists and methods of use: The present invention features epidermal growth factor receptor (EGFR) antagonists. These EGFR antagonists are polypeptide variants of ligands of EGFR. The EGFR ligand polypeptide variants of the invention possess EGFR antagonistic properties and can inhibit at least one EGFR-mediated biological activity such as inhibition of the receptor's kinase activation activity... Agent: Elmore Patent Law Group, PC

20090286723 - Hybrid polypeptides with selectable properties: The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090286733 - Long-acting veterinary polypeptides and methods of producing and administering same: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.... Agent: Pearl Cohen Zedek Latzer, LLP

20090286735 - Method for administering glp-1 molecules: The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.... Agent: Kaplan Gilman & Pergament LLP

20090286731 - Methods and compositions for the treatment of xerostomia: Methods for the treatment of xerostomia are described, hi particular, the present invention takes advantage of the inventors' observation that xerostomia is caused by induction of apoptosis, and can be inhibited by interfering with the cellular processes that trigger apoptosis in cells receiving chemo- and/or radiotherapy.... Agent: Fulbright & Jaworski L.L.P.

20090286725 - Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition: t

20090286734 - Pharmaceutical use of alpha antigen or alpha antigen gene: The α antigen-encoding gene and the α antigen protein suppress the production of interleukin-4 etc., improve the Th2 type cytokine-dominant state, and furthermore inhibit various conditions of allergic diseases such as IgE production, histamine release and eosinophil infiltration, and therefore they are very effective for the prevention or treatment of... Agent: Sughrue Mion, PLLC

20090286730 - Remedies for ischemia: The present invention relates to uses and methods of parathyroid hormone (PTH), preferably PTH (1-34), and/or parathyroid hormone-related peptide (PTHrP), preferably PTHrP (1-34), for recruiting stem cells into tissue suffering from ischemia, wherein said stem cells are preferably capable of repairing and/or regenerating said tissue suffering from ischemia. Accordingly, the... Agent: Foley And Lardner LLP Suite 500

20090286721 - Targeted plasminogen activator fusion proteins as thromobolytic agents: This invention relates to novel fusion proteins, comprising a targeting protein and a plasminogen activator, preferably an antibody that binds to P-selectin, operably linked to the plasminogen activator DSPAalpha1, or analogs, fragments, derivatives, or variants thereof, which are useful as thrombolytic agents. Pharmaceutical compositions containing these fusion proteins, methods of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090286728 - Tooth root formation promoting factors and method for promotion of tooth root formation: The present invention provides a tooth root formation promoting factor and a method for promotion of tooth root formation, which can promote tooth root formation and which are useful in various aspects of dental therapy. Specifically, the tooth root formation promoting factor contains, as an active ingredient, proteins belonging to... Agent: Arthur G. Schaier Carmody & Torrance LLP

20090286726 - Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases: It is described the use of the long pentraxin PTX3 (PTX3) or one of its functional derivatives, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation.... Agent: Lucas & Mercanti, LLP

20090286737 - Erbb interface peptidomimetics and methods of use thereof: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.... Agent: Woodcock Washburn LLP

20090286738 - Gene regulation: The present invention relates to peptides, which impair PBX-dependent regulation of gene transcription and thus have utility in the treatment or prevention of disorders in which aberrant cell division occurs. In particular, the invention provides peptides comprising the amino acid sequence (I), Y1 X1 X2 X3 W X4 X5 X6... Agent: Fulbright & Jaworski, LLP

20090286741 - Methods for improving the structure and function of arterioles: The present invention relates to the unexpected finding that vessels smaller than even the smallest arteries (i.e. arterioles) thicken, become dysfunctional and cause end organ damage to tissues as diverse as the brain and the kidney. This invention provides a method to improve the structure and function of arterioles and... Agent: Weaver Austin Villeneuve & Sampson LLP

20090286740 - Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition: e

20090286742 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells: The invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein.... Agent: Goodwin Procter LLP

20090286739 - Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition: Such amino acids include without limitation L-proline, D-proline, L-hydroxyproline, D-hydroxyproline, L-(O-benzyl)-hydroxyproline, D-(O-benzyl)-hydroxyproline, L-(O-tert. butyl)-hydroxyproline, 4-(O-2-naphtyl)-hydroxyproline, 4-(O-2-naphtyl-methyl)-hydroxyproline, 4-(O-phenyl)-hydroxyproline, 4-(4-phenyl-benzyl)-proline, cis-3-phenyl-proline, cis-4-phenyl-proline, trans-4-phenyl-proline, cis-5-phenyl-proline, trans-5-phenyl-proline, 4-benzyl-proline, 4-bromobenzyl-proline, 4-cyclohexyl-proline, 4-fluor-proline, L-tetrahydroisoquinoline-2-carboxylic acid (L-Tic), all diastereomers of octahydro-indole-2-carboxylic acid (Oic), and all diastereomers of 1-aza-bicyclo[3,3,0]octane-2-carboxylic acid or a residue selected from a group of... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090286743 - Methods and compositions for treating conditions of the eye: Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or... Agent: Goodwin Procter LLP Patent Administrator

20090286745 - Inhibition of alpha-synuclein aggregation: This invention relates to the inhibition of alpha-synuclein aggregation using peptidyl compounds which are retroenantiomers of the alpha-synuclein sequence, in particular retroenantiomers of sequences in the regions between residues 1 to 60 or residues 61 to 96. Peptidyl compounds of the invention may optionally be coupled to doperminergic targeting moieties... Agent: Klarquist Sparkman, LLP

20090286746 - Inhibition of alpha-synuclein aggregation: A synthetic peptide sequence demonstrating neuroprotective and anti-inflammatory functions is disclosed. Methods of use for the synthetic peptide are also provided.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090286744 - Treatment of asthma: Substance P or its analogs are useful for treating asthma. The active agents can be administered orally, intravenously, intramuscularly, intranasally, topically. Disease severity is reduced by substance P treatment.... Agent: Banner & Witcoff, Ltd.

20090286748 - Anti-inflammatory compounds and uses thereof: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell.... Agent: Mccarter & English, LLP Boston

20090286747 - Mntf peptide compositions and methods of use: The present invention relates to novel Motoneuronotrophic Factors (MNTF) peptides and analogs thereof, including compositions capable of promoting the growth and viability of neurons. MNTF peptides between two and six amino acids in length are provided, as well as analogs of these MNTF peptides that are modified by covalent attachment... Agent: Genervon Biopharmaceuticals LLC

20090286749 - Cosmetic composition and a process for preparing said composition: The present invention relates to a cosmetic composition that provides prolonged moisturizing to the skin and a differentiated sensorial, and may be employed in various types of products. This cosmetic composition comprises olive esters, biosaccharide gum-1, a wetting agent of vegetable origin, an emollient of vegetable origin, a silicone and... Agent: Alston & Bird LLP

20090286750 - Use of ribose in lessening the clinical symptoms of aberrant firing of neurons: A method for treating a mammal suffering from a condition caused by aberrant neuron firing is disclosed herein. The method includes administering (e.g., orally administering) to the mammal (e.g., a human patient) in need thereof a therapeutically effective amount of a composition including D-ribose.... Agent: Mueting, Raasch & Gebhardt, P.A.

20090286751 - Progression inhibitor for disease attributed to abnormal accumulation of liver fat: The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for... Agent: Sughrue Mion, PLLC

20090286752 - Oral formulations of cytidine analogs and methods of use thereof: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.... Agent: Jones Day

20090286753 - Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mrnas: The invention relates to ribonucleic acids and oligonucleotide probes useful for detection and analysis of microRNAs and their target mRNAs, as well as small interfering RNAs (siRNAs).... Agent: Clark & Elbing LLP

20090286851 - Compositions and methods for delivering rnai using lipoproteins: This invention relates to new compositions comprising at least one of a single or double stranded oligonucleotide, where said oligonucleotide has been conjugated to a lipophile and to which the conjugated oligonucleotide has been preassembled with lipoproteins. These compositions are effectively in delivering oligonucleotides to mammalian tissue where they effect... Agent: Alnylam/fenwick

20090286850 - Inhibition of emt induction in tumor cells by anti-cancer agents: The present invention provides methods of identifying an agents that inhibit tumor cells from undergoing an epithelial to mesenchymal transition, impair tumor cell mobility, and thus inhibit tumorigenicity. The present invention also provides compositions comprising said agents, and methods for their preparation and use. The present invention also provides methods... Agent: Osi Pharmaceuticals, Inc.

20090286849 - Modulation of insulin like growth factor i receptor expression: The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human... Agent: Morrison & Foerster LLP

20090286854 - Aptamers directed to muci: Aptamers against the glycosylated form of MUC1 are described, along with their use in treatment and diagnosis of conditions associated with elevated production of MUC1.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090286858 - Assays for modulators of asparaginyl hydroxylase: The present invention is directed to methods of identifying an agent which modulates hydroxylation of hypoxia inducible factor (HIF), comprising contacting a HIF asparagine hydroxylase and a test substance in the presence of a substrate of the hydroxylase under conditions in which asparagine in the substrate is hydroxylated in the... Agent: Wilmerhale/boston

20090286857 - Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders: This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject's spinal cord by administering a recombinant viral vector containing the transgene to the spinal cord. The viral... Agent: Genzyme Corporation Legal Department

20090286855 - Interleukin-18 mutants, their production and use: The invention provides mutants of IL-18 with lower affinity to IL-18BP than the wild type IL-18 molecule.... Agent: David S. Resnick

20090286856 - Method of diagnosing breast cancer: Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates between BRC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene... Agent: Townsend And Townsend And Crew, LLP

20090286860 - Method of using adenoviral vectors to induce an immune response: The invention provides a method of inducing an immune response against a human immunodeficiency virus (HIV) in a mammal. The method comprises administering to the mammal an adenoviral vector composition comprising one or more adenoviral vectors encoding two or more different HIV antigens, the production of which induces an immune... Agent: Leydig, Voit & Mayer, Ltd.

20090286853 - Modified oligonucleotides for telomerase inhibition: Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.... Agent: Geron/finnegan Henderson LLP

20090286861 - Phenotypic reversion of pancreatic carcinoma cells: The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic... Agent: Dilworth & Barrese, LLP

20090286859 - Potent lna oligonucleotides for the inhibition of hif-1a expression: The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-(Tx)GxGxcsasasgscsastscscsTxGxT-3′ and 5-(Gx)TxTxascstsgscscststscsTxTxA-3′, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link... Agent: Dechert LLP

20090286852 - Rna containing modified nucleosides and methods of use thereof: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also... Agent: Pearl Cohen Zedek Latzer, LLP

20090286754 - Method of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs: The present invention relates to the use of the compound according to formula (I) Where S is (A) or (B); X is H or F; R1 is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or a phosphodiester group, a (C) or (D) group;... Agent: Coleman Sudol Sapone, P.C.

20090286755 - Potentiator of radiation therapy: The invention provides a radiation therapy potentiator containing, as an effective ingredient, a uracil derivative represented by formula (1) (wherein R1 represents a halogen atom or a cyano group; and R2 represents a 4- to 8-membered heterocyclic group having 1 to 3 nitrogen atoms and optionally having as a substituent... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090286756 - Pharmaceutical compositions for use in the treatment of wounds: A pharmaceutical composition that can be used in the treatment of wounds, comprising at least a sulfated polysaccharide and wherein the polysaccharide/s are in the form of solids as powder, flakes or sheets obtained through a lyophylization process. Particularly, this invention relates to the use of one or more sulfated... Agent: Young & Thompson

20090286757 - Antiviral composition: Chemical compounds, being the alkyl sulfate of sulfated saccharides, particularly, dextrin, dextran, and cyclodextrin, and pharmaceutical compositions containing these compounds. The compounds of the invention provide antiviral activity, particularly in the treatment and prevention of sexually-transmitted diseases. Methods of treating viral infection and preventing viral transmission include administration include administration... Agent: Barbara E. Johnson, Esq.

20090286758 - Substituted n-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity: The present invention provides novel pyrazolines that are useful as cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular disorders, hepatic disorders, and a combination thereof.... Agent: Vance Intellectual Property, PC

20090286759 - Acyloxyalkyl carbamate prodrugs, methods of synthesis and use: Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of making acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of using acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, and pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs 3-aminopropylphosphinic acid and analogs thereof for treating diseases or disorders... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090286760 - Novel compositions and methods for treating hyperproliferative diseases: The invention relates to a composition that includes a first agent selected including an agent that possesses anti-inflammatory activity or acetaminophen, phenacetin, tramadol and the like; a second agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5-monophosphate-activated Protein kinase (AMPK) activator; a... Agent: Fish & Richardson P.C.

20090286763 - Amino acid derived prodrugs of propofol, compositions and uses thereof: The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090286761 - Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device: A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided... Agent: Squire, Sanders & Dempsey LLP

20090286762 - Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions: d

20090286764 - Stable pharmaceutical formulations: Stable pharmaceutical formulations and methods of making same are provided. In a general embodiment, the present disclosure provides a method of making a stable pharmaceutical formulation comprising adding one or more vitrifying additives to an aqueous pharmaceutical solution to raise the glass transition temperature of the aqueous pharmaceutical solution. The... Agent: K&l Gates LLP

20090286765 - Therapeutic agents: A compound of the formula (I): wherein R1, R2, R3, R4, Ar, A, n and m are defined herein, is disclosed as a GlyT1 inhibitor; pharmaceutical compositions containing the compound of the formula (I) are also disclosed as are their use in medicine, for example in the treatment of schizophrenia.... Agent: Merck And Co., Inc

20090286766 - Azolecarboxamide derivative: Provided is an agent for treating or preventing urinary frequency, urinary urgency and urinary, incontinence which are associated with overactive bladder, a lower urinary tract disease such as interstitial cystitis and chronic prostatitis accompanied by lower urinary tract pain, and various diseases accompanied by pain. A novel azolecarboxamide derivative in... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090286768 - Substituted imidazopyr- and imidazotri-azines: Fused pyridine-based bicyclic compounds having the structure of Formula I, as defined herein, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. This abstract does not define or limit the invention.... Agent: Osi Pharmaceuticals, Inc.

20090286767 - Substituted quinolin-4-ylamine analogues: Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for... Agent: Edward Angell Palmer & Dodge, LLP

20090286769 - Compositions and methods for treating hair loss using non-naturally occurring prostaglandins: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.... Agent: Michael Best & Friedrich LLP

20090286770 - Use of staurosporine derivatives for the treatment of multiple myeloma: The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving ras or FGFR3 signalling pathways and l or c-fos transcription, especially for the curative and/or prophylactic treatment of myeloma or multiple Myeloma, and to a method of treating... Agent: Novartis Corporate Intellectual Property

20090286771 - 2-phenoxy- and 2-phenylsulfonamide derivatives with ccr3 antagonistic activity for the treatment of inflammatory or immunological disorders: Provided herein are 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity. These compounds are useful for the treatment of diseases associated with CCR3 activity, including but not limited to, atopic dermatitis, allergic rhinitis, rheumatoid arthritis, Grave's disease, HIV infection, Alzheimer's disease, atherosclerosis and other inflammatory and/or immunological disorders.... Agent: Jones Day

20090286772 - 2-(phenyl or heterocyclic)-1h-phenanthro[9,10-d]imidazoles: The invention encompasses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic... Agent: Merck And Co., Inc

20090286773 - Kinase inhibitors: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the... Agent: Allergan, Inc.

20090286774 - Purinone derivatives as hm74a agonists: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.... Agent: Pepper Hamilton LLP

20090286775 - Bicyclic derivatives as p38 kinase inhibitors: New bicyclic derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090286776 - Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof: Compounds of the formula (I): in which R, R1, R2 and R3 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and processes for the preparation of these compounds.... Agent: Millen, White, Zelano & Branigan, P.C.

20090286777 - 5,6,fused pyrrolidine compounds useful as tachykinin receptor antagonists: The present invention is directed to certain 5,6-fused pyrrolidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations... Agent: Merck And Co., Inc

20090286778 - Macrocyclic compounds and their use as kinase inhibitors: e

20090286779 - Pyrazolopyrimidines as lipid kinase inhibitors: wherein the symbols R1 to R4 are as defined in the specification, tautomers thereof or N-oxides thereof, or (preferably pharmaceutically acceptable) salts thereof, or hydrates or solvates thereof, as well as to related embodiments. The compounds are useful inter alia as protein kinase inhibitors, and thus e.g. useful in the... Agent: Novartis Institutes For Biomedical Research, Inc.

20090286780 - 2-oxochromene derivatives: e

20090286782 - Compounds and methods for kinase modulation, and indications therefor: Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one of Fms protein kinase or Kit protein kinase.... Agent: Foley & Lardner LLP

20090286783 - Compounds and methods for kinase modulation, and indications therefor: Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof derivatives thereof, forms thereof are active on at least one Raf protein kinase. Also described are methods of... Agent: Foley & Lardner LLP

20090286781 - Use of suluble guanylate cyclase acitvators for treating acute and chronic lung diseases: The present invention relates to the use of compounds of the formulae I-VI for manufacturing a pharmaceutical for the treatment of acute and chronic lung disorders such as the respiratory distress syndromes [acute lung injury (ALI), acute respiratory distress syndrome (ARDS)] and the treatment of COPD.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090286784 - Indazole, benzisoxazole, and benzisothiazole kinase inhibitors: e

20090286785 - Pyrimidine derivatives: This invention relates to novel compounds (I) and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090286788 - Active agent combinations with insecticidal and acaricidal properties: i

20090286786 - Compounds having a 4-pyridylalkylthio group as a substituent: wherein A is benzene or an aromatic five-membered heterocycle which optionally is fused with a cycloalkane ring; B is an alkylene; R1 and R2 are hydrogen, hydroxy, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, heterocycle, amino, alkylamino, arylamino or acyl, or R1 and R2 join together to form a heterocycle; X and... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090286787 - Substituted gamma lactams as therapeutic agents: e

20090286789 - Bi-aryl meta-pyrimidine inhibitors of kinases: The invention provides methods of treating a disease selected from systemic sclerosis, rheumatoid arthritis, mastocytosis, and chronic eosinophilic leukemia comprising administering biaryl meta-pyrimidine compounds having the general structure (A) to a subject in need thereof. The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of... Agent: Goodwin Procter LLP Patent Administrator

20090286790 - Organic compounds: e

20090286791 - Amide compounds:

20090286792 - 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and... Agent: Connolly Bove Lodge & Hutz, LLP

20090286793 - Pde4b inhibitors and uses therefor: Compounds active on phosphodiesterase PDE4B are provided. Also provided herewith are compositions useful for treatment of PDE4B-mediated diseases or conditions, and methods for the use thereof.... Agent: Foley & Lardner LLP

20090286794 - Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound: m

20090286796 - Compounds exhibiting type x spla2 inhibiting effect: wherein R20 is —CH2COOH and the like; R21 is —COCONH2 and the like; R22 is C4-C6 alkyl; and the like; R23 is —CH2—R18 wherein R18 is aryl and the like; R24 is hydrogen or C1-C6 alkyl and the like; an optical active compound, a prodrug thereof, or a pharmaceutically acceptable... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090286795 - Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer: The invention relates to a method for screening patients for tumor burden and the use of VEGF-R inhibitors alone or in combination with chemotherapy for the treatment of gastrointestinal, genitourinary, lymphoid and pulmonary (small cell and non-small cell) cancer patients and patients with cancers of neural crest origin having high... Agent: Novartis Corporate Intellectual Property

20090286798 - Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases: e

20090286797 - Novel quinoxaline derivatives and their medical use: This invention relates to novel quinoxaline derivatives having medical utility, to use of the quinoxaline derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the quinoxaline derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which... Agent: Birch Stewart Kolasch & Birch

20090286800 - Glucokinase activators: i

20090286799 - Methods for the treatment of brain edema: The present invention is based on the discoveries that PAN-811 (1) reduces infarct volume, suppresses brain edema and decreases mortality associated with ischemia; (2) blocks veratridine-induced swelling and neuronal cell death; (3) chelates free calcium and inhibits MMP-9 activity; and (4) blocks calcium-induced neuronal cell death and suppresses glutamate-induced calcium... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090286801 - Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands: The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent.... Agent: Stites & Harbison PLLC

20090286802 - High dose folic acid compositions for vascular dysfunction: The present invention relates to treatments for hypertension and more particularly, to the use of high dose folic acid in treating dysfunctional conditions associated with vascular function. High dose folic acid can increase vasodilator-stimulated myocardial blood flow and acutely lower arterial pressure independently of homocysteine lowering.... Agent: Ewards Angell Palmer & Dodge LLP

20090286803 - Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor: e

20090286804 - Metabolites of 1-[6-(1-ethyl-1-hydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one as seratonin receptor antagonists: Metabolites of 1-[6-(1-ethyl-1-hydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one, and use of same. Metabolites of the present invention are as shown in Formula (II): (II) wherein R1, R2 and R3 are as indicated in the specification.... Agent: Pfizer Inc Mary J Hosley

20090286805 - Solubiliazation preparation: A solution-type preparation of lurasidone comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) as an active ingredient and containing at least one substance selected from benzyl alcohol, N,N-dimethylacetamide, lactic acid and propylene glycol.... Agent: Birch Stewart Kolasch & Birch

20090286806 - Isoxazole derivatives as calcium channel blockers: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of isoxazole containing compounds are disclosed of the general formula (1) where Z is N or CHNR3 and (Ar1)2CR4 is optionally substituted benzhydryl.... Agent: Morrison & Foerster LLP

20090286807 - Cyclic amine compound: [wherein R1: H, substitutable alkyl, substitutable alkenyl, substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like; R2: H, substitutable alkyl, substitutable alkenyl, substitutable cycloalkyl or the like; R3, R4; H, substitutable alkyl, substitutable alkenyl, substitutable cycloalkyl or the like; R5, R6: H, substitutable alkyl, substitutable cycloalkyl, substitutable alkoxy or the like;... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090286808 - Opsin stabilizing compounds and methods of use: The present invention provides compositions and methods useful in the treatment and/or prevention of ophthalmic conditions and diseases, such as retinitis pigmentosa, that are dependent upon or related to misfolded opsin proteins in vivo. In addition, screening assays for agents useful in such treatment methods are described.... Agent: Edwards Angell Palmer & Dodge LLP

20090286809 - Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound: e

20090286810 - Pyrimidine non-classical cannabinoid compounds and related methods of use:

20090286811 - Fused pyrimidineone compounds as trpv3 modulators: The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating... Agent: Kaplan Gilman & Pergament LLP

20090286812 - Gpr119 receptor agonists: e

20090286813 - Thioxanthine derivatives and their use as inhibitors of mpo: There are disclosed novel compounds of Formula (I) wherein R1, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090286814 - Hcv protease inhibitors: This invention relates to macrocyclic compounds of formula (I) or (II) shown in the specification. These compounds can be used to treat hepatitis C virus infection.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090286815 - Pyrimidine classical cannabinoid compounds and related methods of use: i

20090286816 - Modulators of metabolism and the treatment of disorders related thereto:

20090286817 - 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use: Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders:... Agent: Lexicon Pharmaceuticals, Inc.

20090286818 - Pyridine non-classical cannabinoid compounds and related methods of use: wherein R1, R2, V, W, X, Y and Z can be as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors.... Agent: Reinhart Boerner Van Deuren S.c. Attn: Linda Kasulke, Docket Coordinator

20090286820 - (r)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their use: Multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use are described. Compounds described include those of formula I:... Agent: Lexicon Pharmaceuticals, Inc.

20090286821 - Inhibitors of tyrosine kinases: wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy... Agent: Novartis Corporate Intellectual Property

20090286819 - Process for preparing the calcium salt of rosuvastatin: An improved process for manufacture of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which is useful for the production of a pharmaceutical useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and atherosclerosis, is described.... Agent: Morgan Lewis & Bockius LLP

20090286822 - Treatment of psoriasis and of other skin disorders associated with inhibition of differentiation of epidermal cells: This invention concerns the use of cyclopamine, a naturally occurring steroidal alkaloid known for over thirty years, for the treatment of psoriasis and achievement of rapid clearance of the psoriatic skin lesions together with the reversion of the histopathological signs of disease to normalcy with no detectable side effects. The... Agent: Vidas, Arrett & Steinkraus, P.A.

20090286823 - Ccr1 inhibitors useful for the treatment of multiple myeloma and other disorders: The invention relates to the use of inhibitors of CCR1 for the treatment of cancers and osteolytic bone disorders. In some embodiments, the invention relates to methods for the treatment of multiple myeloma, smoldering multiple myeloma and secondary bone cancers.... Agent: Millennium Pharmaceuticals, Inc.

20090286824 - Pyridine classical cannabinoid compounds and related methods of use: e

20090286825 - Indole derivatives as crth2 receptor antagonists: Compounds according to formula (I) wherein the radicals R1, R2 and R3 are as herein defined, and wherein Ar represents an aryl group or heteroaryl group, preferably phenyl, n is 1 or 2, and the radical X represents a group selected from —C(Ra)(Rb)—, —C(Ra)(Rb)—C(Ra)(Rb)—, —C(Ra)═C(Ra)—, OC(Ra)(Rb)— or SC(Ra)(Rb)—. These compounds... Agent: Merck And Co., Inc

20090286826 - Pharmaceutical compositions having carboxyvinyl polymer and povidone polymer: The present invention is directed to pharmaceutical compositions, such as ophthalmic gels. The compositions typically include a carboxyvinyl polymer. A povidone polymer is also typically included to stabilize the carboxyvinyl polymer against agents or ingredients (e.g., therapeutic agent) that can otherwise cause instability to the carboxyvinyl polymer.... Agent: Alcon

20090286827 - Novel bi-aryl amines: The present invention relates to novel bi-aryl amines of formula (I) and to pharmaceutically acceptable prodrugs, salts, solvates, hydrates, and N-oxides thereof and to pharmaceutical compositions comprising them, methods of their use, and methods of their preparation.... Agent: Foley And Lardner LLP Suite 500

20090286828 - 2-amino-1-phenylethylcarboxamide derivatives: e

20090286829 - Quinolynylmethylimidizoles as therapeutic agents:

20090286830 - Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists: and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with other agents.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090286831 - Vr1 receptor ligands and u-opioid receptor ligands for the treatment of pain: A pharmaceutical composition comprising i) at least one composition that has affinity to the μ-opioid receptor, and at least one compound that has affinity to the VR1 receptor, or ii) at least one compound, in particular at least one compound corresponding to formula (I), (II), (III), (IV) or (V), that... Agent: Crowell & Moring LLP Intellectual Property Group

20090286832 - Narcotic emulsion formulations for treatment of surgical pain: Methods and compositions of treating a subject for post-surgical pain are provided. In the subject methods, a subject is treated for post-surgical pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl emulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent,... Agent: Bozicevic, Field & Francis LLP

20090286833 - Substituted cyclohexylmethyl compounds: t

20090286834 - Pyridine analogues vi: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.... Agent: Pepper Hamilton LLP

20090286835 - Novel compounds: e

20090286836 - Novel compounds:

20090286837 - Oxadiazole compounds as urokinase inhibitors: The present invention relates to novel compounds which inhibit urokinase-plasminogen activator (uPA), have a high bioavailability and can be administered orally, and to their use as therapeutic active substances for the treatment of disorders associated with urokinase and/or urokinase receptor, for example tumours and metastasis. The invention relates in particular... Agent: Mcdermott Will & Emery LLP

20090286838 - Treatment for cancer: The present invention provides methods for the treatment of tumors, comprising administration of an effective amount of at least one taxoid and an effective amount of at least one benzimidazol carbamate compound of formula (I). The invention also provides a method for the treatment of tumors insensitive to one or... Agent: Knobbe Martens Olson & Bear LLP

20090286839 - Phytonutrient compositions from mushrooms or filamentous fungi and methods of use: This invention is directed to treating disease states or conditions associated with the treatment and prevention of neurodegeneration and neurodegenerative disease states, and treatment of radiation damage. The invention relates to novel phytonutrient compositions and compounds comprising L-ergothioneine and/or selenium. The invention also provides a method of administering these compositions... Agent: Mckee, Voorhees & Sease, P.L.C Attn: Pennsylvania State University

20090286840 - Thiophene-carboxamides useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20090286841 - Certain chemical entities, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090286842 - Naphthylmethylimidizoles as therapeutic agents: m

20090286844 - Carvedilol phosphate: The invention encompasses novel amorphous and crystalline forms of carvedilol phosphate, carvedilol hydrogen phosphate, and carvedilol dihydrogen phosphate as well as methods of making the novel amorphous and crystalline forms. Also disclosed are pharmaceutical compositions comprising the novel amorphous and crystalline forms and uses thereof.... Agent: Kenyon & Kenyon LLP

20090286845 - Carvedilol phosphate: The invention encompasses novel amorphous and crystalline forms of carvedilol phosphate, carvedilol hydrogen phosphate, and carvedilol dihydrogen phosphate as well as methods of making the novel amorphous and crystalline forms. Also disclosed are pharmaceutical compositions comprising the novel amorphous and crystalline forms and uses thereof.... Agent: Kenyon & Kenyon LLP

20090286843 - Macrocyclic compounds as inhibitors of viral replication: The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an... Agent: Knobbe Martens Olson & Bear LLP

20090286846 - Therapeutic use of n-(1h-indolyl)-1h-indole-2-carboxamide derivatives: e

20090286847 - Oncogenic ras-specific cytotoxic compound and methods of use thereof: Embodiments of the present invention provide for methods and compositions comprising an Oncorasin, such as 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1) and/or its analogs or derivatives.... Agent: Bracewell & Giuliani LLP

20090286848 - Novel n-(2-amino-phenyl)-acrylamides: wherein R1 to R4 have the significances given herein, to processes for the manufacture of said compounds as well as medicaments containing said compounds. The compounds according to this invention show anti-proliferative and differentiation-inducing activity and are thus useful for the treatment of diseases such as cancer in humans or... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090286863 - Sulfamatobenzothiophene derivatives: The invention relates to novel compound of the general formula (I), in which R has the meanings indicated in Claim 1, to the preparation thereof and to the use thereof as medicaments. The compounds (I) are inhibitors of steroid sulfatase and are used for the treatment of cancer.... Agent: Millen, White, Zelano & Branigan, P.C.

20090286862 - Therapeutic agent for psychoneurotic disease: e

20090286864 - Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith: Disclosed are a coating agent for drug releasing stents, a method for preparing the same and a drug releasing stent coated therewith. The coating agent for drug releasing stents comprises nanoparticles with a biologically active material entrapped therein, wherein the particles are formed of a polyethyleneimine (PEI)-deoxycholic acid (DOCA) polymer... Agent: Ladas & Parry LLP

20090286865 - Potentiator of antitumoral agents in the treatment of cancer: The present invention relates to a potentiator composition for enhancing therapeutical effect of an antitumoral agent, said composition comprising a terpene or derivative thereof in association with a pharmaceutically acceptable carrier.... Agent: Birch Stewart Kolasch & Birch

20090286867 - Compositions and methods of administering doxepin to mucosal tissue: Compositions and methods for pain relief involve delivery of doxepin to mucosal tissue. Vehicles for administering doxepin may be formulated for sustained release and/or site-specific application to maximize beneficial pain relief locally while minimizing significant adverse side effects.... Agent: Marsh, Fischmann & Breyfogle LLP

20090286866 - Double compartment skincare products comprising avermectin/milbemycin compounds: Double compartment skincare products confine a first compartment containing an anhydrous composition including an active ingredient, and a second compartment, wherein the active ingredient is selected from among compounds of the avermectin family and compounds of the milbemycin family, and are useful as medicaments for the treatment and/or prevention of... Agent: Buchanan, Ingersoll & Rooney PC

20090286868 - Derivatives of dioxan-2-alkyl carbamates, preparation thereof and application thereof in therapeutics: in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3-C6)cycloalkyl-O— or (C3-C6)cycloalkyl(C1-C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090286869 - Flavanols and b-type procyanidins and inflammation: The invention relates to compositions, and methods of use thereof, containing certain polyphenols such as flavanols, procyanidins and derivatives thereof for treating inflammation and/or inflammation-related or associated disease or condition, and/or for the relief of pain, in a subject sensitive to a selective cyclooxygenase-2 (COX-2) inhibitor and/or a subject sensitive... Agent: Nada Jain, P.C.

20090286870 - Cancer treatment using fts and 2-deoxyglucose: Methods of treating cancer by administering effective amounts of a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2-deoxyglucose (2DG) to a patient are disclosed. Pharmaceutical compositions useful in treating cancer containing a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt,... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090286871 - Use of a plant oil product as an agent for increasing the synthesis of skin lipids: The present invention relates to the use of a plant oil product as an agent for increasing the synthesis of skin lipids, especially the lipids of the epidermal skin barrier, in or for the preparation of a cosmetic, pharmaceutical or dermatological composition. The invention also relates to a method for... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090286872 - Oral composition comprising dha and genistein for enchancing skin properties: Composition for oral consumption in the form of a substantially 5 homogeneous aqueous emulsion, suspension or dispersion comprising genistein and docosahexaenoic acid (DHA) and less than 1% by weight of soy protein, wherein the weight ratio of genistein to DHA is in the range of from 1:100 to 1:1, the... Agent: Unilever Patent Group

20090286873 - Ai-2 compounds and analogs based on salmonella typhimurium lsrb structure: This invention relates to crystals comprising apo-LsrB and holo-LsrB. The structure of holo-LsrB identifies a tetrahydroxytetrahydrofuran derived from 4,5-dihydroxy-2,3-pentanedione (DPD) as the active autoinducer-2 (AI-2) molecule in Salmonella typhimurium. The X-ray crystallographic data can be used in a drug discovery method. Additionally the invention provides AI-2 analogs based on this... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090286874 - Anti-aging composition containing phloretin: An anti-aging composition containing: (a) at least one first active ingredient chosen from phloretin and its derivatives; (b) at least one second active ingredient chosen from cinnamic acid, resveratrol, retinol, ascorbic acid, tocopherol, and their derivatives; and (c) at least one non-aqueous organic solvent, with the proviso that if the... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090286875 - Isocystene derivatives for the treatment of pain: The present invention relates to compounds of formula (I): wherein R1, R2, R4 and R4a are as defined herein. The invention also relates to the use of compounds of formula (I) for the treatment of pain.... Agent: Pharmacia Corporation Global Patent Department

20090286876 - Neuroprotective benzoate and benzamide compounds: The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the... Agent: Georgetown University (c/o Sharon Prisco) Office Of Technology Commercialization

20090286877 - Pesticidal/ovicidal composition and pesticidal/ovicidal method: A pesticidal/ovicidal composition comprising (a) 50-99.9 parts by mass of a triglyceride containing not less than 50% of oleic acid as a fatty acid component; (b) 0.1-20 parts by mass of a nonionic surface active agent; and (c) 0-30 parts by mass of a glycerin derivative. The composition according to... Agent: Buchanan, Ingersoll & Rooney PC

20090286878 - Polyol derived anti-microbial agents and compositions: Anti-microbial compositions are provided which comprise as an antimicrobial agent at least one compound derived from a select polyol containing at least 3 hydroxy groups wherein one or more, and often two or more, of the hydroxyls are derivitized to form certain ether, ester, carbonate or carbamate groups which groups... Agent: Joann Villamizar Ciba Corporation/patent Department

20090286879 - Preventive or therapeutic drug for alzheimer-type dementia: It is intended to provide a highly safe preventive or therapeutic drug for Alzheimer-type dementia which can replace the conventional therapies currently used for Alzheimer-type dementia or which can be used together with the conventional therapy to realize high therapeutic effects, characterized in that a ω-3 polyunsaturated fatty acid and... Agent: Birch Stewart Kolasch & Birch

20090286880 - Novel process: The present invention relates to a novel process for the preparation of γ-amino acids, such as (±)-3-(aminomethyl)-5-methyl-hexanoic acid 1, which is a key intermediate in the preparation of the potent anticonvulsant pregabalin, (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid 2.... Agent: Venable LLP

20090286881 - Selected betaines and their uses: A physiologically acceptable, sterile and pyrogen-free solution of betaine dissolved in a physiologically acceptable solvent, having a pH adjusted to from 5.0 to 8.0 with a betaine concentration of from 5 to 500 mg/ml.... Agent: Hovey Williams LLP

20090286882 - Cyclopropylacetic acid derivatives and use thereof: The present application relates to novel cyclopropylacetic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090286883 - Treatment of heart failure and associated conditions by administration of monoamine oxidase inhibitors: Administration of monoamine oxidase inhibitors is useful in the prevention and treatment of heart failure and incipient heart failure.... Agent: Swiss Tanner, P.C. P.o. Box 1749

20090286884 - Hops beta-acid anti-diabetic composition: The invention relates to compositions and processes for reducing the level of blood glucose or ameliorating diabetic symptoms in a subject by treatment with the composition which includes one or more safe and suitable hops acids or hops acid derivatives. More specifically, the process comprises using an ingredient or applying... Agent: Edwards Angell Palmer & Dodge LLP

20090286885 - Ethylene-tetrafluoroethylene phosphate composition: e

20090286886 - Resorbable polymer compositions for use in medicine, dentistry, and surgery: We describe the medical, dental, and surgical uses of modified poly(alkylene) materials which are fully resorbable after implantation into the body, and compositions formulated with such modified poly(alkylene) materials.... Agent: Nixon & Vanderhye, PC

20090286887 - Stabilisation of colorants in cosmetic and dermatological preparations:

  
11/12/2009 > 153 patent applications in 109 patent subcategories. recently filed with US Patent Office
  
11/05/2009 > 153 patent applications in 109 patent subcategories. recently filed with US Patent Office

20090275496 - Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods: The instant invention provides methods for the detection and quantitation of complex peptide mixtures in tissue samples and functional readouts of the results of administration of such complex peptide mixtures. The instant invention further provides methods for administering complex peptide mixtures to a subject in need thereof, the dosage regimen... Agent: Ropes & Gray LLP

20090275495 - Methods and compositions relating to alzheimer's disease: Methods and compositions relating to Alzheimer's disease are provided, including proteins that are differentially expressed in Alzheimer's disease as compared to the normal state. Further provided are methods, particularly experimental paradigms, for the identification of differential expressed proteins that are potential molecular targets for compounds to treat or prevent Alzheimer's... Agent: Dann, Dorfman, Herrell & Skillman

20090275497 - Method for identifying modulators of the activity of ion-channels receptors: The present invention is directed to a method for selecting or identifying a compound capable of modulating the activity of an ion-channels receptor, such as GABA receptor, by measuring the calcium influx via the P2X receptor in presence of its agonist ATP when coupled to said ion-channels receptor in recombinant... Agent: Alston & Bird LLP

20090275499 - Nonstructural protein ns1 as a novel therapeutic target against flaviviruses: The secretion or biological activity of Flaviviruses, as well as the biological activity of NS1 protein from Flavivirus-infected cells, can be inhibited by contacting the cells or the protein with cholesterol inhibitors, sphingolipid inhibitors, glycosphingolipid inhibitors, or molecules comprising an amphipathic, amphiphilic, or hydrophobic region which interacts with NS1 protein.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090275498 - Novel peptides: The invention relates to an isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.... Agent: Frank S. Digiglio, Esq. Scully, Scott, Murphy & Presser, P.C.

20090275500 - Peptide-containing food intake regulator: A safe and widely-applicable food intake regulator can be provided by using at least one peptide selected from the group consisting of a fish or mammalian melanin-concentrating hormone (MCH) and enzymatic digests thereof, which have the activity to suppress food intake.... Agent: Cantor Colburn, LLP

20090275501 - Somatostatin-dopamine chimeric analogs: s

20090275515 - 2-hydroxy-2-phenylthiophenylpropionamides as androgen receptor modulators: Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis,... Agent: Merck And Co., Inc

20090275511 - Analogs of ghrelin substituted at the n-terminal: wherein the definitions of A1 to A28, R1 and R2 are provided for in the specification, with the exception that the N-terminal amino acid must be selected from the group consisting of Inp, 1-Apc and 4-Apc, the pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of said... Agent: Alan F Feeney,esq Biomeasure, Incorporated

20090275513 - Composition and method for preparing plasminogen: Disclosed is both a method for preparing a plasminogen and a method for preparing a reversibly inactive acidified plasmin by activating the plasminogen. The prepared plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluted at a low pH. The... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090275510 - Compositions and methods for inducing or inhibiting activities of selected human cells: Polynucleotides encoding a mutant human carboxylesterase enzyme and polypeptides encoded by the polynucleotides which are capable of metabolizing a prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing cells to a prodrug agent, inhibiting cell growth, treating drug addiction, and facilitating the metabolism of... Agent: Licata & Tyrrell P.C.

20090275505 - Compositions and methods for preventing or treating feline chronic renal failure: The invention provides compositions for preventing chronic feline renal failure comprising from about 28 to about 35% protein and compositions for treating chronic renal failure in felines comprising from about 28 to about 30%, wherein the protein comprises at least about 75% vegetable protein and methods for using such compositions... Agent: Colgate-palmolive Company

20090275512 - Compositions and methods for treating cardiovascular disease and myocardial infarction with dipeptidyl peptidase inhibitors or b type natriuretic peptide analogues resistant to prolyl-specific dipeptidyl degradation: The present invention describes compositions and methods for treating cardiovascular disease and myocardial infarction using dipeptidyl peptidase inhibitors. Also provided are methods for increasing natriuretic peptide function by administering one or more analogues of B type natriuretic peptide that provide increased stability in the presence of prolyl-specific dipeptidyl peptide.... Agent: Wilson, Sonsini, Goodrich & Rosati

20090275516 - Compounds and method for modulating inflammatory reactions: The present invention relates to compounds and methods for modulating, reducing or inhibiting, inflammatory reactions in a patient. Particularly, inflammatory reactions that are targeted by the present invention are cell migration, secretion of toxic products and proteolysis at a site of inflammation. Reduction of inflammation manifestations and reactions occurs by... Agent: Ogilvy Renault LLP

20090275507 - Contraceptive composition: The present invention relates to a contraceptive composition including an effective amount of a dendrimer compound including one or more naphthyl disulphonic acid surface groups, or a pharmaceutically acceptable salt or solvate of the dendrimer compound; and a pharmaceutically acceptable carrier, excipient and/or diluent therefor. The contraceptive composition may also... Agent: Knobbe Martens Olson & Bear LLP

20090275503 - Diastereomeric peptides for modulating t cell immunity: The present invention provides diastereomeric peptides derived from the T Cell Receptor alpha Transmembrane Domain, and lipophilic conjugates thereof, which peptides and conjugates are effective in preventing or treating T cell mediated inflammatory diseases. The invention provides pharmaceutical compositions comprising these diastereomeric peptides and conjugates, and uses thereof for therapy... Agent: Fennemore Craig

20090275517 - G-csf polypeptides and uses thereof: The present invention relates to G-CSF polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090275518 - G-csf polypeptides and uses thereof: The present invention relates to G-CSF polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090275506 - Long lasting natriuretic peptide derivatives: This invention relates to long lasting natriuretic peptide (NP) derivatives. The NP derivative has a NP peptide and a reactive entity coupled to the NP peptide. The reactive entity is able to covalently bond with a functionality on a blood component. In particular, this invention relates to NP derivatives having... Agent: Lando & Anastasi, LLP

20090275509 - Method for stimulating angiogenesis using dkk2 and composition comprising the same: The present invention relates to a method for stimulating angiogenesis using by DKK2 and composition comprising the same. The DKK2 protein of the present invention showed stimulating activities of tube formation on HUVEC, promoting activity of the sprouting of arterial circle tissues and promoting activity of vascular development in the... Agent: Jhk Law

20090275502 - Methods and compositions for enhancing developmental potential of oocytes and preimplantation embryos: The invention relates to compositions and methods for enhancing the developmental potential of oocytes or preimplantation embryos by modulating mitochondrial-associated proteins and/or genomic integrity modifier proteins in the oocytes or preimplantation embryos. In one aspect of the invention, the levels of one or more mitochondrial-associated proteins and/or genomic integrity modifier... Agent: Howson & Howson LLP

20090275504 - Pcsk9 proteins, fragments thereof and methods of modulating pcsk9 phosphorylation and low density lipoprotein (ldlr) degradation: The present invention provide PCSK9 polypeptides, fragments thereof and methods of modulating PCSK9 phosphorylation and low density lipoprotein degradation.... Agent: Clark & Elbing LLP

20090275514 - Use of calmodulin kinase ii inhibitors to treat or prevent heart muscle inflammation: Provided are compositions and methods of treating inflammation of the heart of a subject diagnosed with inflammation of the heart, comprising administering to the subject an effective amount of an inhibitor of Calmodulin Kinase II, whereby the administration of the inhibitor treats inflammation of the heart in the subject. Also... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090275508 - Use of thymosin alpha 1, alone or in combination with ptx3 or ganciclovir, for the treatment of cytomegalovirus infection: It is described the use of thymosin alpha 1 in combination with long pentraxin PTX3 or Ganciclovir, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation.... Agent: Lucas & Mercanti, LLP

20090275520 - Mucin hypersecretion inhibitors and methods of use: Various methods of using peptides are provided where the peptides comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 23 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090275519 - Therapeutic peptidomimetic macrocycles: The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease.... Agent: Wilson, Sonsini, Goodrich & Rosati

20090275521 - Regulation of microphage migration inhibitory factor (mif) activity: The present invention relates to modulating, neutralizing, or inactivating the activity of migration inhibitory factor (MIF). In particularm, the present invention provides methods for modulating, neutralizing, or inactivating MIF activity by complexing MIF with other molecules, preferably a protein, that is capable of associating with MIF. These molecules can be... Agent: Blank Rome LLP

20090275522 - Novel compounds: The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by... Agent: Merchant & Gould PC

20090275523 - Spirocyclic nitriles as protease inhibitors: The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090275524 - Novel hypocholesterolemic compounds: The present invention relates to novel hypocholesterolemic compounds of formula (I) useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as to pharmaceutical compositions comprising said compounds alone or in combination with other active agents... Agent: The Webb Law Firm, P.C.

20090275526 - Mucoadhesive nanoparticles for cancer treatment: The present invention relates to a pharmaceutical composition which includes nanoparticles. The nanoparticles include a glyceryl monooleate or monolinoleate (or other mono fatty acid ester); a chitosan; and a cancer therapeutic agent, such as gemcitabine, taxanes, and hydrophobic cancer therapeutic agents). Also disclosed are methods for preparing such nanoparticles and... Agent: Valauskas & Pine LLC

20090275527 - Skin aging treatment comprising paeoniflorin: The present invention relates to a skin aging treatment comprising paeoniflorin as an active ingredient. Since paeoniflorin is effective in significantly inhibiting and improving intrinsic skin aging, significantly inhibiting and improving DNA impairment and skin wrinkling caused by UV and improving existing wrinkles, a cosmetic composition and a pharmaceutical composition... Agent: Sheridan Ross PC

20090275525 - Use of a lactose-derived c-glycoside compound as an agent for activating and regulating cutaneous immunity: The present invention relates to novel lactose-derived compounds of general formula (I) and to their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmetically or pharmaceutically acceptable medium, intended in particular to prevent and/or limit the appearance... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090275528 - Antituberculous composition comprising oxazole compounds: The present invention provides antituberculous therapeutic drugs with a higher potency. The present invention provides also antituberculous therapeutic drugs containing oxazole compounds represented by (I) general formula (1): [wherein R1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0-6, and R2 represents general formula (A)... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090275634 - Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases: The present invention relates to novel uses of antisense oligonucleotides targeted to the coding region of acetylcholinesterase (AChE) for treating inflammatory disorders other than inflammatory disorders of the central nervous system or the peripheral nervous system innervating voluntary muscles. More particularly, the present invention relates to uses of antisense oligodexoynucleotides... Agent: K&l Gates LLP

20090275638 - Compositions and methods for inhibiting expression of xbp-1 gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1.... Agent: Alnylam/fenwick

20090275632 - Methods of diagnosis and treatment: A method of diagnosing a disease in which an miRNA is expressed at a lower level comprises, in a test sample obtained from a subject, determining the methylation status of at least one gene encoding the miRNA in the sample, wherein the presence of methylation is indicative of the presence... Agent: Foley And Lardner LLP Suite 500

20090275633 - Novel tumour suppressor: A method of diagnosing cancer includes the steps of, in a sample obtained from a subject, determining the level or activity of HDAC2. A reduced level or activity of HDAC2 is indicative of cancer. HDAC2 protein expression is preferably determined. Indirect determination of HDAC2 expression is also possible, preferably by... Agent: Foley And Lardner LLP Suite 500

20090275636 - Picornavirus and uses thereof: The invention is directed to a a clade of newly isolated and identified picornaviruses associated with respiratory infection, and isolated nucleic acids sequences and peptides thereof. The invention also relates to antibodies against antigens derived from the picornavirus. The invention also relates to iRNAs which target nucleic acid sequences of... Agent: Wilmerhale/columbia University

20090275637 - Protein tyrosine phosphatase inhibitors: The present invention provides compositions and methods for binding and/or modulating enzymatic activity of human protein tyrosine phosphatases such as PTP1B. Additionally, the invention provides methods of identifying and using such nucleic acid ligands.... Agent: Wilson, Sonsini, Goodrich & Rosati

20090275641 - Rnai-mediated inhibition of rho kinase for treatment of ocular disorders: RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.... Agent: Alcon

20090275635 - Screening method: The invention provides a method of modulating Wnt signalling comprising modulating Trabid activity. Preferably modulating Trabid activity comprises inhibiting; Trabid activity. The invention also provides a method of reducing TCF transcription, said method comprising reducing Trabid activity. A method for identifying a-modulator of Trabid said method comprising; providing a Trabid... Agent: David S. Resnick

20090275640 - Sirna targeting inner centromere protein antigens (incenp): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20090275631 - Therapeutic antisense oligonucleotide composition for the treatment of inflammatory bowel disease: Disclosed herein is a method for the sustained amelioration and/or treatment of ulcerative colitis comprising rectal administration of a compound comprising an antisense oligonucleotide having the sequence 5′-GCCCAAGCTGGCATCCGTCA-3′, ISIS 2302. The method results in a decrease in the indications of ulcerative colitis for an extended period (greater than 90 days)... Agent: Knobbe, Martens, Olson & Bear, LLP

20090275639 - Usp47 inhibtors and methods to induce apoptosis: The present invention relates to USP47 (ubiquitin specific protease 47) inhibitors and methods for inducing apoptosis or cell death in a target cell. In certain embodiments, the invention relates to methods and kits to screen for related agents that induce apoptosis. Additionally, the invention relates to assays for screening compounds... Agent: Darby & Darby P.C.

20090275642 - Dna composition for eliciting an immune response against tumor-associated macrophages: The present invention provides a DNA composition comprising a DNA minigene construct that encodes for a polypeptide comprising a plurality of immunogenic fragments of a cysteine endopeptidase that is expressed in tumor-associated cells. The immunogenic fragments are joined together serially by a linker peptide between each successive fragment in the... Agent: Olson & Cepuritis, Ltd.

20090275645 - Method to induce neovascular formation and tissue regeneration: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes... Agent: Venable LLP

20090275644 - Novel adaptor protein that binds to mammalian toll-like receptor 3 and gene thereof: A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors,... Agent: Nixon & Vanderhye, PC

20090275643 - Tryptophanyl-trna synthetase-derived polypeptides useful for the regulation of angiogenesis: The invention provides a method for inhibiting ocular neovascularization in a patient. The method comprises administering to a patient an ocular neovascularization inhibiting amount of a water-soluble polypeptide selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 7, and an ocular neovascularization inhibiting fragment thereof, which... Agent: Olson & Cepuritis, Ltd.

20090275529 - Method for improving cardiovascular risk profile of cox inhibitors: A method of reducing the increased risk of cardiovascular events attendant with the use of COX or selective COX-2 inhibitors including restoring disrupted cholesterol metabolic function engendered by the use of the COX or selective COX-2 inhibitors and reducing the production of foam cells caused thereby. The disrupted cholesterol metabolic... Agent: Ostrolenk Faber Gerb & Soffen

20090275530 - Gastric raft composition comprising preferably processed starches for inducing satiety: Provided are methods of inducing satiety in an individual using gastric raft compositions and compositions suitable for such methods. The gastric raft compositions may comprise processed starches such as dextrins. Also described are methods of treating diseases characterised by hypoglycaemia, such as glycogen storage disease (GSD), and diabetes.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090275531 - Method for producing starch networks and initial products: The invention relates to a method for producing starch networks. The method may include preparing a basic starch and preparing a networking starch. The method may further include manufacturing an initial product including the basic starch and the networking starch, and processing the initial product to yield the starch networks,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090275532 - Cosmetic composition comprising an oil: The present invention relates to a cosmetic composition for making up or caring for the skin in the form of a water-in-oil emulsion comprising an aqueous phase and at least 15% by weight, relative to the total weight of the composition, of a fatty phase comprising at least one liquid... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090275533 - Fused bicyclic pyrimidine compounds as aurora kinase inhibitors: e

20090275536 - Antibacterial agents: Described herein are antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical composition.... Agent: Pfizer Inc. Patent Department

20090275535 - Antiviral phosphonate analogs: The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Viksnins Harris & Padys Pllp

20090275534 - Novel pyridopyrazine derivatives, process of manufacturing and uses thereof: The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090275537 - Certain chemical entities, compositions, and methods: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090275538 - Arylmethylidene heterocycles as novel analgesics: The present invention relates to Arylmethylidene heterocycles, compositions comprising an Arylmethylidene heterocycle, and methods useful for treating or preventing pain comprising administering an effective amount of an Arylmethylidene heterocycle. The compounds, compositions, and methods of the invention are also useful for treating or preventing inflammation.... Agent: Clark & Elbing LLP

20090275539 - Nuclear transcription factors regulators: The present invention relates to novel compounds that are nuclear transcription factors (NTF) regulators. The present invention also provides methods for treating, preventing and/or reducing inflammation associated diseases by regulating NTF in the cardiovascular, connective tissue, pulmonary, gastrointestinal, respiratory, urogenital, nervous, or cutaneous systems as well as tumoral and infective... Agent: Schneck & Schneck

20090275540 - Pre-compacted calcium-containing compositions: A pre-compacted materiel comprising one or more calcium-containing compounds and one or more sugar alcohols, wherein the calcium-containing compound having a polycrystallic porous structure. The pre-compacted material is preferably obtained by roller compaction and is suitable for use in the further processing of the pre-compacted material into composition like e.g.... Agent: Edwards Angell Palmer & Dodge LLP

20090275541 - Method for treating neurocognitive dysfunction: wherein: A is a bridge selected from the following radicals: —(CH2)m—, —CH═CH—, —(CH2)p—O—, —(CH2)p—S—, —(CH2)p—SO2—, —(CH2)p—NR1— and —SO2—NR2—, and wherein: m is an integer of from 1 to 3 inclusive; p is an integer selected from 1 and 2; R1 is selected from the group consisting of hydrogen and C1-C5... Agent: Karen Guerrero

20090275542 - Azaheterocyclyl derivatives of androstanes and androstenes as medicaments for cardiovascular disorders: Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. They are useful for the preparation... Agent: Lucas & Mercanti, LLP

20090275543 - Modified glycosaminoglycans, pharmaceutical compositions and methods for oral delivery thereof: This invention provides a composition comprising a depolymerized glycosaminoglycan or derivative thereof covalently linked to a bile acid. This invention also provides a pharmaceutical composition comprising a depolymerized glycosaminoglycan or derivative thereof covalently linked to a bile acid and a pharmaceutically acceptable carrier. Finally, this invention provides a method for... Agent: Robert D. Katz Cooper & Dunham LLP

20090275545 - Medicinal targeted local lipolysis: Aqueous phospholipid systems comprising at least one phospholipid, at least one bile acid and water are suitable for producing medicaments for the treatment of adipose tissue disorders and lead to regression of the pathologically proliferated adipose tissue.... Agent: The Firm Of Hueschen And Sage

20090275544 - Method and kit for reducing the symptoms of peripheral vascular disease: A method for reducing the symptoms of peripheral vascular disease and for improving peripheral circulation wherein a progestin is administered to a subject in need thereof.... Agent: Howard Eisenberg, Esq.

20090275546 - Diagnostic tests and personalized treatment regimes for cancer stem cells: Provided are methods of identifying a metabolic target in a cancer stem cell that include using a microarray to identify intracellular signaling networks within a population of cancer stem cells that respond to a growth factor for the stem cell. Also provided are methods of determining a personalized therapeutic regime... Agent: Quine Intellectual Property Law Group, P.C.

20090275548 - Compounds and methods for activated therapy: Provided herein are compounds for detection, diagnosis and treatment of target tissues or target compositions, including hyperproliferative tissues such as tumors, using sonodynamic and/or photodynamic methods. In particular, photosensitizer and/or sonosensitizer compounds that collect in hyperproliferative tissue are provided.... Agent: Elmore Patent Law Group, PC

20090275547 - Metal complex phosphatidyl-inositol-3-kinase inhibitors: Provided are novel organometallic compounds that inhibit PI3K lipid kinase and phospho-AKT in human melanoma cells, and also inhibit the migration of melanoma cells. The present invention is also directed to methods for inhibiting cancer cell proliferation, migration or both comprising contacting a cancer cell with a disclosed organometallic kinase... Agent: Woodcock Washburn LLP

20090275549 - Use of picoplatin to treat colorectal cancer: The invention provides a method of treatment of colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with 5-FU and leucovorin in a variety of treatment regimens.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090275551 - Fluvastatin for the treatment of patients with a history of muscle related side effects with other statins: The present disclosure relates to method of using fluvastatin, alone or in combination with ezetimibe, be used to (1) lower cholesterol level, (2) treat hypercholesterolemia, (3) treat mixed dyslipidemia and/or (4) inhibit cholesterol biosynthesis in patients who experienced muscle-related side effects (MRSE). The present disclosure also relates to a pharmaceutical... Agent: Novartis Corporate Intellectual Property

20090275552 - Therapy for treating resistant bacterial infections: The invention relates to an improved therapy for treating resistant bacterial infections caused by extended-spectrum β-lactamase (ESBLs)-producing strains in a warm-blooded animal, adjuvant step down therapy, and pharmaceutical compositions for such therapies. The invention also relates to a method for inhibiting bacterial resistance in ESBLs-producing strains so as to have... Agent: Bio Intellectual Property Services (bio Ips) LLC

20090275553 - Dosage regimen of an s1p receptor agonist: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial 3 to 6 days of treatment the daily dosage is raised so that in total the R-fold (R being the accumulation factor) standard daily dosage is administered and thereafter continued at the standard daily dosage... Agent: Novartis Corporate Intellectual Property

20090275554 - Aminocarboxylic acid derivative and medicinal use thereof: P

20090275556 - Aryl sulfonamides useful as inhibitors of chemokine receptor activity:

20090275555 - Substituted indole ligands for the orl-1 receptor: New ligands for the ORL-1 receptor are described, useful for antagonising the activity of said receptors in a patient in need thereof, and for preventing and treating illnesses dependent on the activation of this receptor. The new compounds conform to structural formula (I) wherein R1, R2, R3, R4 are further... Agent: Stetina Brunda Garred & Brucker

20090275550 - Pyridyl amide t-type calcium channel antagonists: The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent: Merck And Co., Inc

20090275557 - Novel composition for treatment of diseases related to activated lymphocytes: The present invention relates to inhibiting proliferation and inducing apoptosis in activated lymphocytes, including T cells and B cells. The invention also provides compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, as well methods for treating diseases associated with activated lymphocytes by administering 5-HT receptor antagonists.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090275558 - Substituted sulfonamide compounds: e

20090275559 - Chronotherapeutic formulations of modified-release calcium channel blocker anti-hypertensive drugs in combination with other anti-hypertensive drugs for 24-hour optimal treatment of hypertension, nocturnal hypertension, and/or hypertension with angina: The present invention relates to formulations of anti-hypertensive drugs. The present invention includes a modified-release formulation of diltiazem hydrochloride that is suitable for once-daily use and which provides delivery of drug either in the early morning hours, or overnight, so as to blunt the natural rise in blood pressure (BP)... Agent: William M. Brown

20090275560 - Organic compounds: The invention relates to organic compounds which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi and parasites of the Leishmania genus such as, for example, Leishmania... Agent: Banner & Witcoff, Ltd.

20090275561 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090275562 - Tolerability of mirtazapine and a second active by using them in combination: A reduction in the side effects of treating with an agent having combined 5HT2/5HT3 and alpha-2 antagonistic activity is obtained by administering an agent having selective norepinephrine reuptake inhibitory or histamine H1 agonist activity. In some embodiments, the invention provides synergistic combinations of 5HT2/5HT3 antagonist/alpha-2 antagonist and selective norepinephrine reuptake... Agent: Wilson, Sonsini, Goodrich & Rosati

20090275563 - Combination of 5-ht7 receptor antagonist and serotonin reuptake inhibitor therapy: Patients suffering from serotonin-mediated diseases or conditions, such as depression, may be treated by administering an effective combined amount of a 5-HT7 receptor antagonist and a serotonin reuptake inhibitor.... Agent: Philip S. Johnson Johnson & Johnson

20090275564 - Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition,... Agent: Jones Day

20090275565 - Substituted aralkyl derivatives: The present invention relates to novel substituted aralkyl derivatives of the general formula (I) and (IIIa), their derivatives, their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, pharmaceutical compositions containing them, use of these compounds in medicine and the intermediates involved in their preparation.... Agent: Nixon & Vanderhye, PC

20090275566 - Bace inhibitors: e

20090275567 - 2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation:

20090275568 - Fused quinoline derivative and use thereof:

20090275569 - Benzotriazine inhibitors of kinases: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.... Agent: Goodwin Procter LLP Patent Administrator

20090275572 - Fab i inhibitors: Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.... Agent: Goodwin Procter LLP Patent Administrator

20090275573 - Imidazolidinone derivatives as 11b-hsd1 inhibitors: m

20090275571 - Morpholinyl and pyrrolidinyl analogs: The present invention relates to morpholinyl, and pyrrolidinyl analogs, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090275574 - Novel compounds-300: e

20090275570 - Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors: The invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.... Agent: Astrazeneca R&d Boston

20090275575 - Benzophenone derivatives useful for inhibiting formation of microtubule: Disclosed herein are novel benzophenone derivatives represented by formula I, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, a pharmacological composition containing the same, and a use of the composition as therapeutic drugs. The benzophenone derivatives have an inhibition activity of microtubule formation and can be... Agent: Lucas & Mercanti, LLP

20090275576 - 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use: R1 represents a hydrogen atom or a (C1-C4)alkyl group; R2 and R3 each represent, independently of one another, a hydrogen atom or a (C1-C4)alkyl group or else R2 and R3 form, with the nitrogen atom which carries them, a pyrrolidinyl, piperidinyl, morpholinyl or 4-alkylpiperazinyl group; and Het represents a heteroaromatic... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090275577 - Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents: Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including... Agent: Pfizer Inc. Patent Department

20090275579 - 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof: m

20090275580 - 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof:

20090275578 - Isoindolone compounds and their use as metabotropic glutamate receptor potentiators: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090275581 - Renin inhibitors: e

20090275582 - Bi-aryl meta-pyrimidine inhibitors of kinases: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.... Agent: Goodwin Procter LLP Patent Administrator

20090275583 - Antiviral compounds and use thereof: The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20090275584 - Biocidal combinations comprising imazalil: The present invention relates to combinations of imazalil, or a salt thereof, and a biocidal compound which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of imazalil, or a salt thereof, together with one or more biocidal compounds selected from tolylfluanid, dichlofluanid,... Agent: Philip S. Johnson Johnson & Johnson

20090275585 - Novel compounds and therapeutic use thereof for protein kinase inhibition: e

20090275586 - Heterocyclic inhibitors of pde4: The present invention is directed to potent and selective heterocyclic compounds, useful as inhibitors of phosphodiesterase 4 (PDE4), compositions comprising the same, and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of PDE4 activity are also provided, as well as methods for the treatment of inflammatory... Agent: Global Patent Group - Kal

20090275589 - Pyridazine compound and use thereof: e

20090275590 - (1-azinone)-substituted pyridoindoles: wherein R1 is H or optionally substituted alkyl; R2, R3, R4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF3, and —CN; G is —CR12R13—NR5— or —NR5—CR12R13; R5; is H, optionally substituted alkyl, optionally substituted heterocycle, —C(═O)—R6, —C(═O)—O—R7, or —C(═O)—NR19R20; R6 and R7 are each optionally substituted alkyl... Agent: Heslin Rothenberg Farley & Mesiti PC

20090275591 - 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitor: The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the... Agent: Edwards Angell Palmer & Dodge LLP

20090275592 - Heterocyclic modulators of pkb: e

20090275587 - Methods of treating ischemic related conditions: The present invention relates to methods of treating ischemia-related conditions by administering to a patient in need of such methods certain thiosemicarbazone compounds. Preferred embodiments of the present invention relates to methods of treating specific ischemia-related conditions, including but not limited to Alzheimer's disease, Parkinson's disease, Coronary artery bypass graft... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090275588 - Novel sulfonamide compounds: The invention relates to novel sulfonamide compounds and their use as orexin receptor antagonists.... Agent: Hoxie & Associates LLC

20090275593 - 3 substituted n-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as kinase inhibitors: The invention relates to 3-substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidine compounds, their use as kinase inhibitors, new pharmaceutical formulations comprising said compounds, said compounds for use in the diagnostic or therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of diseases or for the manufacture of pharmaceutical formulations useful... Agent: Novartis Institutes For Biomedical Research, Inc.

20090275594 - 3-hydrazone piperazinyl rifamycin derivatives useful as antimicrobial agents: The present invention is directed to novel 3-hydrazone piperazinyl rifamycin derivatives, pharmaceutical compositions containing them and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes.... Agent: Philip S. Johnson Johnson & Johnson

20090275595 - Method for reduction, stabilization and prevention of rupture of lipid rich plaque: There is to provide is an agent for reduction of a lipid rich plaque, stabilization of a lipid rich plaque and/or prevention of rupture of a lipid rich plaque in an atherosclerotic lesion comprising an effective amount of 2-[4-[2-(benzimidazole-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide (hereinafter, referred to as compound 1), its pharmaceutically acceptable salt or... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090275597 - Methods of treating cns disorders: The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20090275596 - Treatment of neurodegenerative disorders with thiourea compounds: e

20090275598 - Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders:

20090275599 - Therapeutic or prophylactic agent for multiple sclerosis: A therapeutic or prophylactic agent for multiple sclerosis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for multiple sclerosis according to... Agent: Darby & Darby P.C.

20090275600 - Modified pyrimidine glucocorticoid receptor modulators: The present invention provides a novel class of modified pyrimidine compounds and compositions and methods of using the compounds as glucocorticoid receptor modulators.... Agent: Townsend And Townsend And Crew, LLP

20090275601 - Novel pyriproxyfen compositions: New pesticidal compositions comprising pyriproxyfen and methyl esters of C16-C18 fatty acids and having low volatile organic compound (VOC) content are provided. Methods of use and ready-to-use products are also provided.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090275602 - Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use: wherein R1a, R1b, R1c, B, R3, R4, R5 and W of Formula I, and R1a, R1b, R1c, R2, R2a, R3, R4, R5, A1, A2, A3, A4, W, X, Z, m and n of Formula II are defined herein. The invention also provides compounds of Formula III, sub-Formulas II-A-II-D, sub-Formulas III-A-III-D... Agent: Amgen Inc.

20090275603 - Nf- kb inhibitors and uses thereof: A new class of imidazolines as 4-position esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of... Agent: Peter G. Carroll Medlen & Carroll, LLP

20090275604 - M3 muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090275605 - 3,11 b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammatory disease: The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a proliferative disease or an inflammatory disease, the compound being 3,11b-cis-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090275606 - Heterocyclic compounds as mek inhibitors: e

20090275609 - Carboxamide compounds and methods for using the same:

20090275608 - Methods of diagnosing and treating parp-mediated diseases: Disclosed are methods of identifying a disease treatable with modulators of differentially expressed genes in a disease, including at least PARP modulators, by identifying the level of expression of differentially expressed genes, including at least PARP, in a plurality of samples from a population, making a decision regarding identifying the... Agent: Bipar Sciences Inc. C/o Mofo

20090275607 - Tetrahydro isoquinoline derivatives, preparation methods and medicinal uses thereof: A kind of tetrahydro isoquinoline derivatives (I), their preparation methods, medicine compositions and medicinal uses thereof, especially their uses as κ-opioid receptor excitant in pain relieving, which belongs to the medicine chemistry. The substituents R1, R2, R3, R4 of general formula (I) are defined as the description.... Agent: Christie, Parker & Hale, LLP

20090275610 - Tricyclic opioid modulators: The invention is directed to compounds of Formula (I) useful as delta and mu opioid receptor modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.... Agent: Philip S. Johnson Johnson & Johnson

20090275611 - Compounds which modulate the cb2 receptor: Compounds are provided which bind to and are agonist, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula (I) wherein R1, R2, R3, X and Ar have the meanings given in the specification, and the preparation and use thereof. The compounds are valuable CB2 receptor... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090275612 - Compound with antimalarial activity and antimalarial drug containing the same as active ingredient: Compounds with high antimalarial activity; and antimalarial drugs containing the same as an active ingredient. There are provided compounds with antimalarial activity represented by the chemical formula: (wherein R1 is H, Cl or OCH3; R2 is H or CH3; R3 is CH, CH2, C(CH3), CH(CH3) or C(CH3)2; Ar is imidazole,... Agent: Edwards Angell Palmer & Dodge LLP

20090275613 - Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: The present invention discloses novel compounds of Formula I: (I) possessing 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes,... Agent: Eli Lilly & Company

20090275614 - Methylphenidate derivatives and uses of them: e

20090275615 - Method of treating thermoregulatory disfunction with paroxetine: The present invention relates to a method for treating a patient suffering from a thermoregulatory dysfunction, especially hot flashes and flushes associated with hormonal changes due to naturally occurring menopause (whether male or female) or due to chemically or surgically induced menopause. The method is also applicable to treating the... Agent: Foley And Lardner LLP Suite 500

20090275616 - Straightforward entry to 7-azabicyclo[2.2.1]heptane-1-carbonitriles and subsequent synthesis of epibatidine analogues: The present invention relates to a group of substituted-7-azabicyclo-[2.2.1]heptyl derivatives with biological activity. The present invention also relates to synthetic methods for producing said substituted-7-azabicyclo-[2.2.1]heptyl derivatives. The present invention also relates to certain intermediates for producing such substituted-7-azabicyclo-[2.2.1]heptyl derivatives, as well as a synthetic method for producing such intermediates. The... Agent: Clark & Elbing LLP

20090275617 - Aryl-substituted nitrogen-containing heterocyclic compounds: [in the formula, A1, A2 and A3 independently represent a carbon atom or a nitrogen atom, and one or two of A1, A2 and A3 represent a carbon atom; R1 represents a lower alkyl group or the like; R2 represents a phenyl group which may be substituted with a halogen... Agent: Merck And Co., Inc

20090275618 - 1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as cb1 receptor modulators: Compounds and pharmaceutical compositions of Formula (I) by blockade of the CB1 receptors via an inverse agonism mechanism which are useful for reducing body weight in mammals, cognitive impairment associated with schizophrenia, mitigating treatment emergent weight gain observed during treatment with antipsychotics and have increased bioavailability.... Agent: Eli Lilly & Company

20090275619 - Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes,... Agent: Merck And Co., Inc

20090275621 - 1, 3, 4-oxadiazol-2-ones as ppar delta modulators and their use thereof: e

20090275620 - Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase:

20090275622 - Nizatidine formulations: Pharmaceutical formulations comprising nizatidine or salts thereof. Further the invention relates to liquid pharmaceutical formulations comprising nizatidine or salts thereof.... Agent: Dr. Reddy''s Laboratories, Inc.

20090275623 - Alpha-amino acid derivatives and medicaments containing the same as an active ingredient: (wherein, R1, R2, R3, R4, X and Y are as defined in the claims) or pharmaceutically acceptable salts, prodrugs or solvates thereof. The derivatives of formula (1) have βARK1 inhibitory activity and are useful for preventing or treating heart failure. Moreover, the derivatives of formula (1) also have antitumor activity,... Agent: Birch Stewart Kolasch & Birch

20090275624 - Inhibitors of cdc phosphatases: A subject of the present invention is novel compounds comprising 2 or 3 benzothiazole-4,7-dione- or benzooxazole-4,7-dione-type units, which inhibit the cdc25 phosphatases, in particular cdc25-C phosphatase. These compounds can in particular be used in the treatment of cancer.... Agent: Hunton & Williams LLP Intellectual Property Department

20090275625 - Novel thiazolidin 4-one derivatives: The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.... Agent: Hoxie & Associates LLC

20090275626 - Pharmaceutical composition for prevention or treatment of neurogenic pain: The purpose of the present invention is to provide agents useful for the prevention or treatment of a neuropathic pain. That is, the present invention provides agents for the prevention or treatment of neuropathic pain such as painful diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, or postoperative or posttraumatic chronic pain... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090275627 - Alpha2b and alpha2c agonists: Described herein are compounds that can be useful as bioactive agents. More specifically, the compounds described herein can be useful as both α2B and α2C adrenergic agonists. Methods of synthesis and administration of the compounds are also disclosed.... Agent: Allergan, Inc.

20090275628 - Substituted spiro-compounds and the use thereof for producing medicaments: The present invention relates to substituted spiro compounds, to processes for preparing them, to medicaments comprising these compounds and to the use of these compounds for producing medicaments.... Agent: Crowell & Moring LLP Intellectual Property Group

20090275629 - Therapy for the treatment of disease: Disclosed herein are pharmaceutical compositions comprising various combinations of an antimuscarinic or an anticholinergic agent, a compound that causes stimulation of salivary glands, and a compound that relieves constipation. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.... Agent: Techlaw LLP

20090275630 - Cosmetic composition comprising an imidopercarboxylic acid derivative and a n-acylated amino acid ester: Composition containing, in a physiologically acceptable medium, at least one imidopercarboxylic acid compound and at least one N-acylated amino acid ester of formula (A) as described herein.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090275646 - Therapeutic compounds: m

20090275647 - Taxane derivative composition: A stable, absolutely ethanol free composition of docetaxel that prevents alcoholic intoxication or anaphylactic shock. The composition can be in the form of a stable injectable composition that includes a taxane derivative, wherein the composition includes a mixture of docetaxel, one or more stabilizer, one or more surfactant, or more... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090275649 - Compositions and methods for identifying modulars of trpv2: It has now been discovered that certain cannabinoids specifically activate TRPV2 channel activity. Based on the discovery, novel compositions and methods for screening, identifying and characterizing compounds that increase or decrease the biological activity of a TRPV2.... Agent: Philip S. Johnson Johnson & Johnson

20090275648 - Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists... Agent: Myers Bigel Sibley & Sajovec

20090275650 - 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof: e

20090275651 - Alcanoic acid amides substituted by saturated o-heterocycles: Compounds of the general formula (formula I) in which the meanings of the substituents R1 to R6 are as indicated in claim 1, have renin-inhibiting properties and can be used as medicines.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090275652 - Biofilm formation inhibitor composition: A drug and a composition for inhibiting biofilm formation are provided. A biofilm formation inhibitor composition containing the following component (A): (A) at least one or more selected from compounds represented by Formula (1) to Formula (4): wherein R1 to R5 each represent an alkyl group or the like; EO... Agent: Birch Stewart Kolasch & Birch

20090275653 - Polymorphic forms of ladostigil tartrate: The invention provides for solid state chemistry of ladostigil tartrate, particularly polymorphic forms of ladostigil tartrate, and processes for the preparation thereof.... Agent: Winston & Strawn LLP Patent Department

20090275654 - Pharmaceutical gallium compositions and methods: The present invention provides novel pharmaceutical gallium compositions, as well as methods for their preparation and methods for treating conditions and diseases such as cancer, hypercalcemia, osteoporosis, osteopenia, and Paget's disease.... Agent: Diehl Servilla LLC

20090275655 - Pharmaceutical gallium compositions and methods: The present invention provides novel pharmaceutical gallium compositions, as well as methods for their preparation and methods for treating conditions and diseases such as cancer, hypercalcemia, osteoporosis, osteopenia, Paget's disease, and infections.... Agent: Diehl Servilla LLC

20090275656 - Medicinal compositions of salts, chelates and/or free acids of alpha hydroxyl organic acids and related processes and methods: Processes are described for the production of an isolated medicinal composition for administration to mammals which comprises an effective amount of a free acid, salt or chelate of at least one naturally occurring form of an alpha hydroxyl organic acid comprising combining at least one naturally occurring form of an... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090275657 - Fatty acid antimicrobial: The novel antimicrobial composition is disclosed including from about 60 to 95% of a lipophilic polar solvent such as propylene glycol, ethylene glycol, or isopropanol and from about 0.5 to 5% of a mixture of C8 to C14 fatty acids. Other constituents of the present invention may include water, an... Agent: Smith Law Office

20090275658 - Method for producing a raw oil from mixtures of micro-organisms and plants, oil produced according to said method and specific uses of the thus produced oil and, optionally, additional refined oil: The invention relates to a method for producing a raw oil from micro-organisms and plants, oil produced according to said method and specific uses of the thus produced oil and, optionally, additional refined oil in foodstuffs, in food supplements, or in cosmetic or pharmaceutical compositions.... Agent: Hammer & Associates, P.C.

20090275659 - Phenyl acetic acid derivatives as inflammation modulators: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.... Agent: Amgen Inc.

20090275660 - Stable parenteral formulations of tigecycline: The present invention relates to stable parenteral formulations of tigecycline and process of preparation thereof, wherein the formulation comprises of an edetate, a pH modifying agent or an antioxidant, such that the formulation remains stable for at least 45 hours.... Agent: Ranbaxy Inc. Intellectual Property Dept.

20090275661 - Preparation of the formaurindicarboxylic acid base and its derivations and use: A pharmaceutical composition comprising at least 0.1 μmol of formaurindicarboxylic acid or its derivatives in 1 kg of pharmaceutically acceptable carrier. The pharmaceutical composition of claim 1 wherein the composition is in the form of solution prepared using aqueous alcali or water.... Agent: Ostrolenk Faber Gerb & Soffen

20090275662 - Injectable veterinary composition: Injectable veterinary composition comprising a fluorinated chloramphenicol or thiamphenicol derivative and a solvent system comprising an ether of 1,2-ethanediol oligo- or polymers, and a pyrrolidone solvent.... Agent: Intervet/schering-plough Animal Health

20090275663 - Method for producing a disinfecting agent: The invention relates to medicine, in particular to sanitary and hygiene, more specifically to methods for producing a disinfecting agent for decontaminating different types of water, including drinking water. The inventive disinfecting agent producing method by dissolving quaternary ammonium compounds in water in the presence of an active additive in... Agent: Collard & Roe, P.C.

20090275664 - Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases: Peptide conjugates in which cytocidal and cytostatic agents, such as polyamine analogs or naphthoquinones, are conjugated to a polypeptide recognized and cleaved by enzymes such as prostate-specific antigen (PSA) and cathepsin B are provided, as well as compositions comprising these conjugates. Methods of using these conjugates in the treatment of... Agent: Morrison & Foerster LLP

20090275665 - Enhanced biological potential of greater than 99% pure form of 1, 7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione over corresponding 95% pure form-therapeutic and agricultural applications thereof: Disclosed are novel and enhanced anti-fungal properties of greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione in comparison with the corresponding 95% pure form, said greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione being devoid of 5-Hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-3-heptanone and 3,5-Dihydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-heptane. The inventors disclose the uses of greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione... Agent: Sabinsa Corporation

20090275666 - Condensation products, method for their production and use thereof in medicaments, as disinfectants or as a tannin: s

20090275667 - Use of allicin as preservative, as disinfectant, as antimicrobial or as biocidal agent: The present invention provides the use of allicin in (i) the treatment of leishmanimis; (b) as a disinfectant or biocidal treatment of aquatic species; (iii) as an antimicrobial agent for animal feed; (iv) as a preservative agent in foodstuffs; (v) as a water disinfectant or biocide; (vi) as an antiparasitic... Agent: Connolly Bove Lodge & Hutz LLP

20090275668 - Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation: The present invention provides a sprayable gel-type skin/mucosa-adhesive preparation comprising a gel formulation which contains an active pharmaceutical ingredient in a gel base material comprising a skin/mucosa-adhesive agent and an administration system comprising the preparation.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090275669 - Flavor and fragrance composition: A flavor and fragrance composition with a cooling sensation effect comprising 1-(2-hydroxy-4-methylcyclohexyl)ethanone represented by the formula (1). The flavor and fragrance composition is added to a beverage or food product, a fragrance or cosmetic product, a daily utensil product, an oral composition, or a pharmaceutical product in the range of... Agent: Mcdermott Will & Emery LLP

20090275670 - Dog pheromone formulation and delivery system: The present invention is directed to a dog behavioral control system comprising a low melting point polymer or copolymer, an unsaturated long chain fatty alcohol, and a dog-appeasing pheromone to produce a solid slow release generator of the pheromone. The system is useful for making animal collars and the like.... Agent: Jacqueline S Larson

20090275671 - Two component bone cement composition for vertebroplasty: The invention is directed to an intrinsically radio-opaque two component bone cement, comprising a first component which contains at least one acrylate monomer and a second component which contains at least one initiator for the polymerisation of said acrylate monomer, wherein the at least one iodine containing radio-opacity providing polymer... Agent: Banner & Witcoff, Ltd.

20090275672 - Sustained-release tablet production process: A process is provided for efficiently producing sustained-release tablets having superior sustained-release properties capable of inhibiting the initial elution of a drug and allowing the drug to be completely eluted after a prescribed amount of time has elapsed. A process for producing sustained-release tablets comprising: dry granulating a mixture composed... Agent: Kenyon & Kenyon LLP

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 2.29711 seconds

PATENT INFO